




Contents lists available at ScienceDirect

Critical Reviews in Oncology / Hematology

journal homepage: www.elsevier.com/locate/critrevonc

Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

Joaquim Bellmunt^a, Begoña P. Valderrama^b, Javier Puente^c, Enrique Grande^d,
M. Victoria Bolós^e, Nuria Lainez^f, Sergio Vázquez^g, Pablo Maroto^h, Miguel Ángel Climentⁱ,
Xavier Garcia del Muro^j, José Ángel Arranz^k, Ignacio Durán^{l,*}

^a Department of Medical Oncology, Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab, Harvard Medical School, Boston, MA, USA

^b Department of Medical Oncology, Virgen del Rocío University Hospital, Sevilla, Spain

^c Department of Medical Oncology, San Carlos Clinic University Hospital, San Carlos Health Research Institute, Madrid, Spain

^d Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain

^e Pfizer, Madrid, Spain

^f Department of Medical Oncology, Navarra University Hospital, Pamplona, Spain

^g Department of Medical Oncology, Lucus Augusti University Hospital, Lugo, Spain

^h Department of Medical Oncology, Santa Creu and Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain

ⁱ Department of Medical Oncology, Valencia Institute of Oncology Foundation, Valencia, Spain

^j Department of Medical Oncology, Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain

^k Department of Medical Oncology, Gregorio Marañón University Hospital, Madrid, Spain

^l Department of Medical Oncology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain

ARTICLE INFO

Keywords:

Urothelial carcinoma (UC)
Bladder cancer
Platinum-based chemotherapy
Checkpoint inhibitors (CPIs)
Avelumab
Switch maintenance
Antibody drug-conjugate (ADC)

ABSTRACT

Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. Nonetheless, recent therapeutic developments including the paradigm shift of first-line maintenance therapy with avelumab after response or stabilization on platinum-based chemotherapy, along with the incorporation of new drug classes in further lines of treatment such as antibody drug-conjugates and fibroblast growth factor receptor inhibitors have reshaped the field leading to better outcomes in this patient population. This article reviews the current state of the art with an overview on UC management, recent advances, and the upcoming strategies currently in development in advanced UC with an insight into the biology of this disease.

1. Introduction

Bladder cancer is the tenth most common form of cancer globally, with 573,278 new cases and 212,536 related deaths estimated in 2020 (World Health Organization, 2020). Bladder cancer is almost four times more common in men than in women, being the sixth most common tumor and the ninth leading cause of cancer death in men (Bray et al., 2018). The median age at diagnosis is 73 years, with cigarette smoking increasing the risk of bladder cancer four-fold in western society (Saginala et al., 2020).

The most frequent histology of bladder cancer is urothelial carcinoma (UC). UC can occur anywhere along the urinary tract. More than

90% of UCs originate in the bladder, while the remaining originate in the renal pelvis, ureters, and urethra (National Cancer Institute, 2022). Less common types of bladder cancer named “variant histological types” are squamous cell carcinoma (3%), adenocarcinoma (2%), and small cell carcinoma (<1%), among others. Mixed histology is often seen, consisting predominantly of UC with areas of other types of variant histologies (Humphrey et al., 2016).

UCs are classified into three categories depending on the invasion of the bladder wall and the presence of metastasis: non-muscle invasive bladder cancer (NMIBC), that is limited to the urothelium not beyond the lamina propria; muscle invasive bladder cancer (MIBC), that grows in the lamina propria and invades the muscle layer; and unresectable

* Correspondence to: Marqués de Valdecilla University Hospital. IDIVAL, Avenida Cardenal Herrera Oria s/n, 39011 Santander, Cantabria, Spain.
E-mail address: ignaciojose.duran@sccsalud.es (I. Durán).

<https://doi.org/10.1016/j.critrevonc.2022.103683>

Received 13 January 2022; Received in revised form 7 April 2022; Accepted 11 April 2022

Available online 16 April 2022

1040-8428/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

locally advanced or metastatic UC (mUC), when it has spread to regional lymph nodes, abdominal or pelvic wall or distant sites (Bochner et al., 2017).

At diagnosis, around two thirds of patients present with NMIBC, of whom 10–15% will progress to invasive forms, being mainly high-risk cases. About 30% of the patients are diagnosed with MIBC and 10–15% present initially with locally advanced or metastatic disease. Additionally, around 50% of MIBC patients will relapse after radical cystectomy and develop metastasis (National Cancer Institute, 2022; Bajorin, 2016; Bellmunt et al., 2014; Milowsky et al., 2016).

Overall survival (OS) at 5 years considering all bladder cancer stages is approximately 77% in the US. However, OS is especially poor in the majority of patients with mUC (4.6% at 5 years in the pre-immunotherapy era) (Saginala et al., 2020).

The goal of treatment in NMIBC is to prevent recurrence and/or progression to invasive forms. Patients receive complete transurethral resection of the bladder tumor (TURBT). Subsequent treatment could include intravesical instillation with mitomycin C or Bacillus Calmette-Guérin (BCG) according to the risk group (Bajorin, 2016; Bellmunt et al., 2014; National Cancer Institute, 2022). Treatment of NMIBC remained unchanged until the introduction of checkpoint inhibitors (CPIs). In a phase II single arm trial (KEYNOTE-057), pembrolizumab in 103 patients with BCG-unresponsive carcinoma in situ (CIS) who were ineligible for or declined radical cystectomy showed a complete response (CR) rate at 3 months of 41%, with a median duration of CR of 16.2 months. Forty-six percent of initial responders had a CR that lasted at least 12 months (Balar et al., 2021). Based on this trial, pembrolizumab was granted US Food and Drug Administration (FDA) approval in January 2020 for patients with BCG-unresponsive high-grade NMIBC - CIS with or without papillary tumors (Food and Drug Administration, 2022a). Several trials are underway to evaluate the role of CPIs in the treatment of naïve NMIBC either alone or combined with BCG (POTOMAC trial, NCT03528694; CREST trial, NCT04165317; ALBAN trial, NCT03799835; and KEYNOTE-676 trial, NCT03711032), or after BCG failure (CheckMate 7G8 trial, NCT04149574; KEYNOTE-676 trial, NCT03711032; CREST trial, NCT04165317; and ADAPT trial, NCT03317158). Intravesical gene therapy with nadofaragene firadenovec also shows efficacy in this therapeutically challenging disease state (N = 103; 53% CR at 3 months; 24% CR at 12 months) with not yet regulatory approval (Boorjian et al., 2021).

In the MIBC setting, the goal is to increase the potential for cure while minimizing morbidity (Bajorin, 2016). Although bladder preservation strategies through trimodality therapy combining complete TURBT, radiation, and concurrent chemotherapy (CT) are increasing, radical cystectomy and pelvic lymph node dissection are still the gold standard for the management of MIBC (Gakis et al., 2013; Witjes et al., 2021). If the patient is eligible for cisplatin treatment, neoadjuvant cisplatin-based combination CT should be given (Witjes et al., 2021; Advanced Bladder Cancer ABC Meta-analysis Collaboration, 2005). Adjuvant cisplatin CT is not considered as standard of care (SoC) in these patients, although it is recommended for patients with high-risk tumors who did not receive neoadjuvant CT (Witjes et al., 2021; Leow et al., 2014).

The use of CPIs may also change the SoC in the near future for MIBC disease. While promising results have been reported for single arm phase II trials (NABUCCO, PURE-01, ABACUS, MDACC, NCT, and others), some neo-adjuvant phase III clinical trials are underway looking to confirm the benefit in this setting (NIAGARA, NCT03732677; CA017-078, NCT03661320; KEYNOTE-866, NCT03924856; KEYNOTE-B15/EV-304, NCT04700124; CA045-009, NCT04209114) (Rouanne et al., 2020). Additionally, several phase II trials are currently testing the combination of CPIs with CT in the neoadjuvant setting and some of them have already reported preliminary results (Rose et al., 2021; Martinez Chanza et al., 2021; Gupta et al., 2020; Funt et al., 2021).

Three randomized phase III trials have investigated the role of CPIs (atezolizumab, nivolumab, and pembrolizumab) in the adjuvant setting

for MIBC who are at high risk of recurrence following resection. Whereas IMvigor-010 trial did not meet its primary endpoint of disease-free survival (DFS) for atezolizumab compared to observation (Bellmunt et al., 2021), CheckMate 274 has recently demonstrated that adjuvant nivolumab is associated with both statistically significant and clinically meaningful improvement in DFS compared to placebo in patients with MIBC following radical surgery, both in the intention-to-treat (ITT) population and in patients with programmed death-ligand 1 (PD-L1) $\geq 1\%$. OS data is still immature (Bajorin et al., 2021). Adjuvant nivolumab has received recent FDA approval in August 2021. Observation versus placebo used differently in the control arms of these two studies might potentially explain the differences observed on trial outcome. Results from the Ambassador study with pembrolizumab in this setting are still pending at the time of writing this review (NCT03244384). Furthermore, based on a retrospective biomarker analysis performed on the IMvigor010, another phase III trial with atezolizumab as adjuvant therapy is now accruing in select patients with high-risk MIBC who are positive for circulating tumor DNA (ctDNA+) post cystectomy (IMvigor011; NCT02302807).

Treatment in the unresectable locally advanced or metastatic setting is mainly palliative. For the past almost 30 years, cisplatin-based CT followed by observation was the SoC for patients who could tolerate cisplatin. In patients ineligible for cisplatin, carboplatin-based CT followed by observation was recommended (Bellmunt et al., 2014).

First-line platinum-containing CT in metastatic treatment-naïve patients result in objective response rates (ORR) in the range of 40–60% and disease control rates of nearly 80% of patients, however, progression-free survival (PFS) and OS are short because of primary or acquired CT resistance (von der Maase et al., 2000; Dogliotti et al., 2007; de Santis et al., 2012; von der Maase et al., 2005). Real-world studies have shown that in the pre-immunotherapy era, a considerable proportion of mUC patients were not receiving any systemic therapy at the time of progression, with only 25–55% of patients receiving second-line. In addition, outcomes with second-line therapy remain suboptimal because of rapid disease progression (Cheeseman et al., 2020; Aly et al., 2019; Galsky et al., 2018; Fisher et al., 2018; Niegisch et al., 2018; Flannery et al., 2019; Swami et al., 2021).

CPIs have shown antitumor activity against locally advanced and mUC and have shaped the management of the disease (Lopez-Beltran et al., 2021). These drugs were initially assessed as salvage treatment following progression on platinum-containing CT and showed favorable efficacy and safety profiles compared with cytotoxic CT (Plimack et al., 2017; Sharma et al., 2017; Rosenberg et al., 2016; Patel et al., 2018; Massard et al., 2016). Consequently, five PD-L1/PD-1 inhibitors (atezolizumab, nivolumab, pembrolizumab, avelumab, and durvalumab) received FDA approval and three PD-L1/PD-1 inhibitors (atezolizumab, nivolumab, and pembrolizumab) received European Medicines Agency (EMA) approval for the treatment of advanced UC in this setting.

With the aim of bringing forward the use of CPIs to the upfront setting, numerous therapeutic approaches have been developed, including the use of single agent CPI, the upfront combination of CT and CPIs, and the switch to a CPI as maintenance after non-progression to first-line CT. In PD-L1-positive patients ineligible for cisplatin, pembrolizumab or atezolizumab were a treatment option based on the results of phase II studies (Galsky et al., 2020; Powles et al., 2020; Powles et al., 2021; Powles et al., 2020). However, recently, FDA has restricted the use of pembrolizumab only to platinum ineligible patients irrespective of PD-L1 expression.

The objective of this article is to review latest advances and the paradigm shift in advanced UC treatment, including the role of immunotherapy and the recent approval of avelumab (anti-PD-L1) as first-line maintenance treatment of locally advanced or metastatic UC that has not progressed with first-line platinum-containing CT, the approval of two antibody drug-conjugate (ADC), enfortumab vedotin (EV) and sacituzumab govitecan (SG), after progression on platinum-based CT and CPIs, and of erdafitinib in patients with fibroblast growth factor (FGFR)

mutations or gene fusions in second or subsequent lines.

2. Therapeutic approach for locally advanced or metastatic disease

2.1. State of the art of first-line treatment

The standard first-line treatment for advanced or mUC is a platinum-containing combination (NCCN Guidelines®, 2021; Powles et al., 2021). Combinations of gemcitabine and cisplatin (GC) and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) plus granulocyte colony-stimulating factor regimens are accepted options in patients fit for cisplatin. The triplet combination of paclitaxel, gemcitabine and cisplatin (PGC) is another option for patients with mUC (Bellmunt et al., 2012). In the EORTC-30987 study, an increase in the ORR, a trend towards an improvement in PFS and a trend towards longer OS (3 months difference) was observed. Interestingly, PGC was associated with a significant improvement in OS among patients with primary bladder cancer compared with GC (median OS: 15.8 versus 12.7 months; HR 0.85; 95% CI 0.72–1.02; $p = 0.075$). An increase in febrile neutropenia with a lower incidence of thrombocytopenia and bleeding were observed in the PCG arm. These results suggest that PGC may be a treatment option for patients with mUC and indicate that it should be used for those with the bladder as primary origin. First-line GC and ddMVAC provide a median PFS of 7.7 and 9.5 months respectively, a median OS of 14.0 and 15.1 months and an ORR of 49.4% and 64% respectively (von der Maase et al., 2000; von der Maase et al., 2005; Sternberg et al., 2006). PCG provides a median PFS of 8.3 months, a median OS of 15.8 months and an ORR of 56%.

Around half of patients are ineligible or unfit for cisplatin according to the “Galsky criteria” (Galsky et al., 2011), because of impaired renal function (creatinine clearance < 60 ml/min), Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 , peripheral neuropathy grade ≥ 2 , New York Heart Association (NYHA) Class III heart failure, and/or hearing loss grade ≥ 2 . In these patients considered unfit, carboplatin and gemcitabine (CbG) combination is a recommended option with lower activity than what is observed with cisplatin combinations (41% ORR and a median PFS and OS of 6 months and 9 months, respectively) (de Santis et al., 2012). Normally, four to six cycles of either cisplatin or carboplatin-based CT are given and then treatment is discontinued due to the lack of evidence of further treatment benefit and concerns about cumulative toxicity impairing patients' quality of life (von der Maase et al., 2000).

The limited long-term benefit obtained with CT led to a search for new strategies to prolong OS in first-line cisplatin-eligible and cisplatin-ineligible patients. CPIs have antitumor activity against UC in first-line cisplatin-ineligible patients and as salvage treatment in platinum-refractory patients. Switching to maintenance therapy with avelumab plus best supportive care (BSC) following non-disease progression with platinum-containing CT has demonstrated a statistically significant improvement in OS over BSC alone and is recommended as the new SoC in advanced and mUC patients with CR, partial response (PR) or SD to first-line platinum-containing CT by treatment guidelines in UC (NCCN Guidelines®, 2021; Powles et al., 2021; Cathomas et al., 2022). Combinations of CPI plus platinum-based CT or CPI plus CPI have not shown an OS benefit so far and additional studies are underway, which will be discussed later in this review (Galsky et al., 2020; Powles et al., 2020; Powles et al., 2021).

2.1.1. Checkpoint inhibitor monotherapy in first-line cisplatin-ineligible patients

Pembrolizumab and atezolizumab single agents were approved in 2017 and 2018 by the FDA and the EMA, respectively, in first-line for cisplatin-ineligible patients whose tumors express PD-L1. Additionally, and only in the United States, approval was granted for patients who were not eligible for any platinum-containing CT regardless of PD-L1

expression status (Food and Drug Administration, 2022b; European Medicines Agency, 2022). Accelerated approvals were initially based on the single-arm phase II KEYNOTE-052 study (Balar et al., 2017; Vuky et al., 2020; O'Donnell et al., 2021) and the IMvigor210 (Balar et al., 2017; Balar et al., 2018; Rosenberg et al., 2021) trials and are contingent upon confirmation from the first-line phase III studies KEYNOTE-361 (Powles et al., 2021) and IMvigor130 (Galsky et al., 2020). More recently, FDA has granted full approval and updated the indication of pembrolizumab restricting its use in first-line for the treatment of patients who are not eligible for any platinum-containing CT (Food and Drug Administration, 2021).

In KEYNOTE-052, pembrolizumab long-term results after 5 years of follow-up demonstrated an ORR of 28.9% with 9.5% of CRs, with a median duration of response (DOR) of 33.4 months. The median OS was 11.3 months, with a 24- and 36-month OS rate of 35.3% and 22.1%, respectively. Patients with a combined positive score (CPS) $\geq 10\%$ had better outcomes than patients with CPS $< 10\%$; (ORR 47.3% vs. 20.7%, and OS 18.5 months vs. 9.7 months, respectively) (O'Donnell et al., 2021).

In IMvigor210, atezolizumab long-term results after a minimum follow up of 5.8 years showed an ORR of 28% with a 12% CR. The ORR was 28% in patients with PD-L1 $\geq 5\%$ in tumor-infiltrating immune cells (IC 2/3) and 22% in patients with PD-L1 $< 1\%$ (IC0/1). Median OS was 16.3 months, with a 2-year OS rate of 41%. Median DOR was 59.1 months in the all-comer population and 53.5 months in patients with PD-L1 IC0/1 tumors (IC2/3 median DOR not yet reached) (Rosenberg et al., 2021).

Preliminary analyses of the monotherapy arms from the phase III trials KEYNOTE-361 (pembrolizumab) and IMvigor130 (atezolizumab) assessing upfront CPI monotherapy versus platinum-based CT alone in advanced UC, identified a lower OS rate among patients with low PD-L1 expression treated with a CPI alone than among those who received platinum-based CT (Galsky et al., 2020; Powles et al., 2021). Based on these data, in 2016–2017 both the EMA and the FDA restricted the use of pembrolizumab and atezolizumab to patients with high expression of PD-L1 (Food and Drug Administration, 2022b), based on a predefined score and specific antibody against PD-L1 biomarker (22C3 or SP142). Due to the hierarchical design of both studies, the monotherapy arms were not formally tested, and results of these trials suggest that neither pembrolizumab nor atezolizumab monotherapy improved OS (Galsky et al., 2020; Powles et al., 2021).

A recent exploratory analysis from the IMvigor130 trial assessing efficacy outcomes for the atezolizumab monotherapy arm in cisplatin-ineligible patients based on PD-L1 status showed a median OS of 18.6 months for atezolizumab monotherapy ($n = 50$) versus 10 months for the CT arm ($n = 43$) (HR 0.53; 95% confidence interval [CI] 0.30–0.94) in PD-L1 positive (IC2/3) patients. Despite the exploratory nature of this analysis, it suggested an improved OS with atezolizumab monotherapy versus CT in cisplatin-ineligible PD-L1-positive patients (Galsky et al., 2021).

However, this trend was not observed in a similar exploratory analysis from KEYNOTE-361 assessing efficacy outcomes for pembrolizumab monotherapy versus CT in cisplatin-ineligible patients, which showed a median OS of 15.6 months for the pembrolizumab arm ($n = 84$) and 13.5 months for the CT arm ($n = 89$) (HR 0.82; 95% CI 0.57–1.17) in PD-L1 CPS $\geq 10\%$ patients. Unlike IMvigor130, this analysis suggested that the PD-L1 CPS biomarker for pembrolizumab did not predict outcome with pembrolizumab in cisplatin-ineligible patients (Powles et al., 2021) and these results led the FDA to restrict pembrolizumab to platinum-ineligible patients (Food and Drug Administration, 2021).

Another recent phase III trial, the DANUBE study, also failed to show a statistically significant improvement for durvalumab monotherapy versus CT in the upfront setting of patients with high expression of PD-L1 (14.4 months versus 12.1 months, HR 0.89; 95% CI 0.71–1.11), although a survival benefit was observed with the combination of

durvalumab and tremelimumab in PD-L1-positive patients (secondary study endpoint) (Powles et al., 2020).

2.1.2. First-line maintenance approach

2.1.2.1. The rationale for maintenance therapy. Despite the activity seen with first-line platinum-based CT combinations, most patients with advanced UC will experience disease progression soon after concluding first-line treatment. Therefore, strategies to extend or improve the initial benefit achieved with platinum-based CT are required.

A possible solution could be the use of maintenance strategies, defined as a continuous treatment with a well-tolerated drug or combination of drugs after completing first-line induction therapy. Two maintenance approaches can be generally considered for patients who achieved an initial benefit with first-line treatment: i) a switch maintenance that means consecutive treatment with a different agent not used before; and ii) a continuation maintenance or deintensification that refers to the prolongation of one of the agents previously received as part of the induction treatment (Lee and Chung, 2014).

When designing a maintenance strategy, few points need to be considered. It is critical to carefully select as an induction treatment an agent or combination of agents capable of inducing a relevant degree of cytoreduction and somehow “priming” the tumor and its microenvironment to facilitate the action of a subsequent drug. More importantly, the subsequent regimen should not only be active by extending or increasing previously obtained responses but also should have a favorable safety profile, allowing long-term administration without impairment of patients’ quality of life with ideally, an easy administration schedule. Additionally, the timing use of the sequentially utilized agent

is critical. It has been hypothesized that a CT-free interval could decrease tumor resistance by removing a selective pressure, thereby allowing the re-expression of drug targets and the reversal of genetic and epigenetic changes, consequently leading to a less heterogeneous tumor and conditioning new sensitivity to the CT (Tonini et al., 2013).

Given these premises and the current treatment scenario in mUC, an attractive strategy seems to be a sequential approach of CT (a highly active induction strategy) followed, in those patients who achieved benefit, by immunotherapy maintenance (active and with low toxicity, allowing for long-term administration). Furthermore, there is a biological rationale for the sequential approach of these treatment options. On the one hand, CT is known to overcome tumor resistance by different mechanisms such as induction of immunogenic cell death, depletion of immunosuppressive cell types, increasing the presentation of tumor antigens, or triggering T-cell infiltration towards immunotherapy-resistant tumors. Recent data from IMvig130 suggests that GC enhances anti-tumor immunity, particularly when is combined with atezolizumab, potentially through the induction of immunogenic cell death (Galsky et al., 2021). Therefore, administering CT first could modulate tumor resistance and eventually potentiate an immunotherapy effect (Emens and Middleton, 2015; Pfirsche et al., 2016). On the other hand, there could be a mechanistic explanation to justify this sequential approach using as a model, the cancer immunoediting framework, where elimination, equilibrium, and escape represent the different stages of the immune system-tumor interaction (Schreiber et al., 2011) (Fig. 1).

During the escape stage, when the tumor overcomes the immune system and proliferates, the anti-tumor effect of CT could help to restore the equilibrium phase or even lead to an elimination stage by decreasing




Fig. 1. Model of the cancer immunoediting framework.

or eliminating tumor burden. Nevertheless, these chemo-mediated effects may be transitory until tumor cells acquire immune escape mechanisms, and so the sequential administration of immunotherapy as a maintenance schedule may be crucial increasing the immune elimination and/or allowing the immune system to prolong the equilibrium phase, thereby delaying disease progression.

A switch-maintenance strategy may also enable more patients to receive a CPI within first-line therapy, rather than reserving it for the minority of patients who can receive it in second-line (Galsky et al., 2018; Flannery et al., 2019; Simeone et al., 2019). Previous attempts exploring the maintenance approach in mUC using sunitinib or lapatinib in genomically selected patients failed to show any benefit (Powles et al., 2017; Grivas et al., 2014). Vinflunine in the maintenance setting showed a PFS benefit without survival improvement (García-Donas et al., 2017; Bellmunt Molins et al., 2020).

2.1.2.2. First-line maintenance strategy with checkpoint inhibitors. Two randomized trials have been reported showing activity of switch maintenance therapy based on CPI upon non-progression from induction with platinum-based CT in the upfront setting of locally advanced or mUC: namely the Hoosier Cancer Research Network GU14-182 (HCRN GU14-182) trial and the JAVELIN Bladder 100 trial (Powles et al., 2020; Galsky et al., 2020). Comparative study design and main clinical outcomes of these two trials are shown in Table 1.

The first trial providing data with CPIs in the maintenance setting was the phase II randomized double-blinded investigator-initiated trial HCRN GU14-182, which compared pembrolizumab maintenance with placebo in 108 patients with advanced UC (Galsky et al., 2020). After receiving up to 8 cycles of platinum-based CT upfront, pembrolizumab showed a benefit in terms of PFS versus placebo (HR 0.65; p = 0.04). However, that difference was not translated into an improvement in OS (HR 0.91; 95% CI 0.52-1.59), probably due to the study design with small sample size and because of allowing placebo patients to crossover to pembrolizumab (51.9%) (Galsky et al., 2020).

Definitive evidence for the strategy of switch maintenance with CPI in advanced UC came from the phase III JAVELIN Bladder 100 trial (Powles et al., 2020). A total of 700 patients who did not have disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) criteria after an induction with 4-6 cycles of first-line platinum-based CT (GC or CbG) and a treatment-free interval (TFI) of 4-10 weeks from the last dose of CT, were randomized to receive avelumab at 10 mg/kg every 2 weeks plus BSC or BSC alone. Randomization was stratified according to the best response to first-line CT (CR or PR vs. SD) and to the metastatic site when first-line CT was initiated (visceral vs. non-visceral). Overall, 51% had PD-L1-positive tumors and 27% had upper urinary tract involvement. The primary endpoint was OS, assessed among the entire population and among those with PD-L1-positive tumors. Importantly, all the endpoints were measured post-randomization (after CT). At the prespecified interim analysis, the median follow-up was more than 19 months in each treatment arm. OS at 1 year was 71.3% in the avelumab group and 58.4% in the control group in the entire population. The median OS was 21.4 months and 14.3 months, respectively (HR 0.69; 95% CI 0.56-0.86). With a longer follow-up of more than 21 months in each arm, the benefit is maintained (median OS 22.1 vs. 14.6 months; HR 0.70; 95% CI 0.564-0.862) (European Medicines Agency, 2022). Clinical impact was also observed when medians of survival were compared (7.5 months of median OS increase) despite the fact that up to 43.7% of patients in the BSC group received subsequent treatment with an anti-PD-L1/PD-1 agent, favoring a maintenance approach versus second-line CPI treatment (Powles et al., 2020; European Medicines Agency, 2022). Avelumab significantly prolonged OS in the PD-L1-positive population too; OS at 1 year was 79.1% in the avelumab group and 60.4% in the control group (HR 0.56; 95% CI 0.40-0.79) (Powles et al., 2020; European Medicines Agency, 2022).

Avelumab maintenance treatment also improved PFS. The PFS rate

Table 1

Trial design and main clinical outcomes of the maintenance strategy in advanced UC.

	Phase III JAVELIN Bladder 100 (Powles et al., 2020; European Medicines Agency, 2022) N = 700	Phase II HCRN GU14-182 (Galsky et al., 2020) N = 108
Trial design	<ul style="list-style-type: none"> Phase III Open label Avelumab plus BSC vs. BSC Endpoints are measured post-randomization (after CT) 	<ul style="list-style-type: none"> Phase II Double-blinded Pembrolizumab vs. placebo Endpoints are measured post-randomization (after CT)
Crossover	<ul style="list-style-type: none"> No crossover to avelumab allowed 	<ul style="list-style-type: none"> Crossover to pembrolizumab allowed upon progression on placebo
Prior CT	<ul style="list-style-type: none"> 4-6 cycles of induction platinum-based CT before randomization 	<ul style="list-style-type: none"> ≤ 8 cycles of induction CT before randomization
Dosing	<ul style="list-style-type: none"> Avelumab Q2W OS 	<ul style="list-style-type: none"> Pembrolizumab Q3W PFS by Investigator
Primary endpoint		
Tumor assessments	<ul style="list-style-type: none"> Every 8 weeks 	<ul style="list-style-type: none"> Every 12 weeks
Countries / Sponsorship	<ul style="list-style-type: none"> Global / Industry 	<ul style="list-style-type: none"> US / Investigator
Median PFS (ITT)	<ul style="list-style-type: none"> PFS by IRC Avelumab plus BSC: 3.7 months BSC alone: 2.0 months (IC 95% 1.9-2.7) Stratified HR 0.62 (95% CI 0.52-0.75); p < 0.001 	<ul style="list-style-type: none"> PFS by investigator Pembrolizumab: 5.4 months Placebo: 3.0 months HR 0.65 (Log-rank p = 0.04)
Median OS (ITT)	<ul style="list-style-type: none"> Avelumab plus BSC 22.1 months BSC alone: 14.6 months Stratified HR 0.70 (95% CI 0.564, 0.862) 	<ul style="list-style-type: none"> Pembrolizumab: 22 months Placebo: 18.7 months HR 0.91 (95% CI 0.52, 1.59)
Subsequent treatment with CPI (%)	43.7%	51.9%

Avelumab maintenance in first-line in patients with advanced or metastatic UC that have not progressed with platinum-based CT is the only treatment approved in this setting.

BSC: best supportive care; CI: confidence interval; CPI: checkpoint inhibitor; CT: chemotherapy; HCRN: Hoosier Cancer Research Network; HR: hazard ratio; IRC: Independent Review Committee; ITT: intention-to-treat; OS: overall survival; PFS: progression-free survival; NR: not reached; Q2W: once every 2 weeks; Q3W: once every 3 weeks.

at 12 months was 30% in the avelumab plus BSC versus 13% in the BSC arm (HR 0.62; 95% CI 0.52-0.75); the median PFS was 3.7 versus 2.0 months in the entire population. In the PD-L1-positive population, the PFS rate at 12 months was 36% in the avelumab plus BSC arm versus 15% in the BSC arm (HR 0.56; 95% CI 0.431-0.728); the median PFS was 5.7 versus 2.1 months, respectively (Powles et al., 2020).

The safety profile of avelumab during the maintenance period was consistent with the previously reported for avelumab monotherapy. Only 10.2% of infusion-related reactions were reported in the avelumab plus BSC arm and none of them were grade ≥ 3. The most frequent category of immune-related adverse events was thyroid disorders (12.2%) (Powles et al., 2020). Up to 11.9% of patients discontinued avelumab and 9.0% received high doses of steroids due to adverse events. The tolerability of avelumab plus BSC is supported by a no detrimental impact on clinically relevant patient-related outcomes compared to BSC alone, which is acceptable and reinforces the use of first-line avelumab maintenance as a new SOC for patients with advanced UC whose disease has not progressed with upfront platinum-containing CT (Powles et al., 2020). Treatment was given until progression.

Avelumab maintenance therapy showed a consistent trend towards improving survival in all subgroups of patients reported in the JAVELIN Bladder 100 trial (Powles et al., 2020). OS and PFS were longer with avelumab maintenance plus BSC versus BSC alone, both in patients who had received first-line GC and in those treated with a CbG. The former represented 52% and 59% in the experimental and control arm, respectively, and the latter 42% and 35% in each of the study arms. Moreover, the benefit for the maintenance arm with avelumab was independent of the type of response achieved with first-line CT (around 72% of patients in each arm showed a PR/CR after CT and 28% SD) (Powles et al., 2020). This was also irrespective of the duration or number of cycles of first-line CT received prior to randomization (Loriot et al., 2021) and of the length of the TFI from end of CT to the start of the maintenance treatment. In the TFI 4 to < 6 weeks subgroup, median OS was 19.9 vs. 13.5 months. In the TFI 6 to < 8 weeks subgroup, median OS was 26.1 vs. 21.0 months for avelumab + BSC and BSC alone, respectively (Sridhar et al., 2021). Subgroup analysis (as seen in the forest plot) might suggest that patients with PD-L1-negative status (OS HR 0.86; 95% CI 0.62–1.18; PFS HR 0.64; 95% CI 0.48–0.85) and patients who achieve CR with CT (25% in each arm) (OS HR 0.81; 95% CI 0.47–1.38; PFS HR 0.65; 95% CI 0.45–0.96) could have a reduced degree of benefit from avelumab than the overall population in terms of OS, although the PFS is significantly improved. Moreover, data in the CR group was not mature and PD-L1 was not a stratification factor, its value is discussed later on. Patients with visceral metastasis (HR 0.82; 95% CI 0.62–1.09; PFS HR 0.73; 95% CI 0.58–0.93), especially those with liver involvement (OS HR 0.92; 95% CI 0.54–1.56; PFS HR 0.96; 95% CI 0.59–1.55), might also benefit less from maintenance therapy, although this could reflect the worse prognosis associated with liver metastases and is only a hypothesis from the trial results (Grivas et al., 2020). Although the treatment sequence after progression to avelumab maintenance remains to be clarified, data for subsequent lines from JAVELIN Bladder 100 suggest that CT including platinum-based CT rechallenge and targeted therapies like erdafitinib are treatment options (Grivas et al., 2021).

Based on the JAVELIN Bladder 100 results, avelumab received FDA and EMA approvals in June 2020 and January 2021, respectively, for the maintenance treatment of patients with locally advanced or mUC who have not progressed with first-line platinum-containing CT and was added as a preferred or recommended treatment in the National Comprehensive Cancer Network (NCCN) (Category I) and European Society for Medical Oncology (ESMO) (category IA) guidelines, respectively (Powles et al., 2020; NCCN Guidelines®, 2021; Powles et al., 2021; Food and Drug Administration, 2022c; Inacio, 2022).

2.1.3. Other strategies in first-line

2.1.3.1. Checkpoint inhibitor plus chemotherapy as first-line combination approach. Two large phase III randomized studies evaluated this approach in first-line advanced or mUC: IMvigor130 and KEYNOTE-361 (Galsky et al., 2020; Powles et al., 2021). IMvigor130 was a three-arm trial that compared atezolizumab plus platinum-based CT and atezolizumab monotherapy versus placebo plus platinum-based CT (Galsky et al., 2020). The selection of GC or CbG in the CT regimen was based on investigator's choice. Co-primary efficacy endpoints were PFS and OS for atezolizumab plus CT versus CT, and following a hierarchical approach, OS for atezolizumab monotherapy versus CT was analyzed only if OS was positive for the combination arm versus CT. Patients were stratified according to PD-L1 immune cell expression status, Bajorin risk factor score, and investigator choice of platinum-based therapy (GC or CbG).

A total of 1213 patients were included. The final PFS analysis revealed a statistically significant difference in median PFS of 8.2 months for atezolizumab plus CT versus 6.3 months for CT (two months' increase in median PFS; HR 0.82; 95% CI 0.70–0.96) (Galsky et al.,

2020). The second interim OS analysis with a median follow-up of 13.3 months did not cross the prespecified interim efficacy boundary for statistical significance (HR 0.84; 95% CI 0.71–1.00; one-sided $p = 0.026$) (Galsky et al., 2021). Longer follow-up is still required for final OS analysis. The combination of atezolizumab and CT was in general well tolerated, with a safety profile consistent with each individual agent (Galsky et al., 2020).

KEYNOTE-361 was an open-label three-arm trial that compared pembrolizumab plus platinum-based CT and pembrolizumab monotherapy versus CT alone (Powles et al., 2021). Randomization was stratified by investigator choice of platinum-based CT and the positivity for PD-L1 CPS. Co-primary endpoints were PFS and OS, using a hierarchical strategy: first, testing both PFS and OS for pembrolizumab plus CT versus CT alone; and followed by OS for pembrolizumab alone versus CT in CPS $\geq 10\%$ and the entire population if the above analysis was positive.

The study included 1010 patients. With a median follow up of 31.7 months, differences in PFS and OS between pembrolizumab plus CT versus CT alone did not reach statistical significance according to the protocol prespecified criteria (one-sided p value boundary for significance of 0.0019 and 0.0033 for PFS and OS final analysis, respectively). Median PFS for pembrolizumab plus CT and CT alone was 8.3 and 7.1 months, respectively (HR 0.78; 95% CI 0.65–0.93). Median OS was 17.0 and 14.3 months, respectively (HR 0.86; 95% CI 0.72–1.02). DOR was 28.2 months versus 6.2 months with CT plus pembrolizumab and CT alone, respectively.

2.1.3.2. Two checkpoint inhibitors as first-line combination approach. The combination of two CPIs with different mechanisms of action and acting at different stages of immune activation is also an interesting approach (Harris et al., 2016). CTLA-4 is thought to regulate T-cell proliferation in the early stages of the immune response, primarily in lymph nodes, whereas PD-1 suppresses T-cells at later stages in peripheral tissues (Buchbinder and Desai, 2016).

The DANUBE study is a randomized phase III trial that compared durvalumab, an anti-PD-L1 agent, with or without tremelimumab, an anti-CTLA-4 agent, administered for up to a total of 4 doses, with standard CT (GC or CbG) up to a maximum of 6 cycles as first-line treatment for mUC (Powles et al., 2020). Randomization was stratified based on cisplatin eligibility, PD-L1 status (high vs. low expression) and presence/absence of liver and/or lung metastasis. The co-primary endpoints were OS of durvalumab versus CT for the population with high expression of PD-L1, and OS for durvalumab plus tremelimumab versus CT for the entire population.

A total of 1032 patients were included. The OS for durvalumab versus CT in the population with high expression of PD-L1 (tumor cells and/or immune cells [TC/IC ≥ 25]) was not significant (HR 0.89, 95% CI 0.71–1.11). The OS for durvalumab plus tremelimumab versus CT in the entire population was 15.1 months versus 12.1 months, respectively (HR 0.85; 95% CI 0.72–1.02). Evaluated as a secondary endpoint in the PD-L1-high expression population, the combination of durvalumab plus tremelimumab showed a statistically significant improvement for OS versus CT of 17.9 months versus 12.1 months, respectively (HR 0.74; 95% CI 0.59–0.93). Although in the entire population CT had the highest ORR (49%), in the PD-L1-high expression population (exploratory analysis) durvalumab plus tremelimumab arm had an ORR comparable to CT (47%). However, the median DOR was higher for the durvalumab and durvalumab plus tremelimumab versus CT arm (9.3 vs. 11.1 vs. 5.7 months in the entire population, and 18.5 vs. 10.0 vs. 5.8 months in the PD-L1-high expression population, respectively) (Powles et al., 2020). A recent exploratory analysis also suggests a role for the TC/IC ≥ 25 algorithm with the Ventana SP263 biomarker assay as a predictor of longer survival in patients treated with the combination of durvalumab plus tremelimumab or even durvalumab monotherapy (Bellmunt et al., 2021).

Furthermore, the results from the combination arm of nivolumab plus ipilimumab versus CT from the CheckMate 901 trial (Galsky et al., 2018) are still pending and will provide additional evidence on the role of the combination of two CPI in this setting.

2.1.3.3. Checkpoint inhibitor plus antibody-conjugated drug or targeted therapies as first-line combination approach. ADC therapies, such as EV, have shown promising results in second-line and further survival advantage in third-line treatment of mUC and are expected to move to upfront lines in combination with CPIs (Rosenberg et al., 2020; Powles et al., 2021; Rosenberg et al., 2019; Balar et al., 2021). EV is a Nectin-4 directed ADC comprised of a fully human anti-Nectin-4 IgG1 conjugated to the small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimide caprol valine-citrulline linker (Chau et al., 2019; Food and Drug Administration, 2019). The antibody binds with high affinity to tumor cells expressing Nectin-4 that then internalizes and releases the chemotherapeutic agent, which arrests the cell cycle and induces apoptosis.

The phase I/II EV-103 study analyzed the combination of EV and pembrolizumab as first-line treatment in patients with advanced UC ineligible for cisplatin (Rosenberg et al., 2020; Friedlander et al., 2021). Five patients were included in the dose escalation phase, and 40 were included in the expansion cohort (Rosenberg et al., 2020). At a median follow-up of 24.9 months, confirmed ORR was 73.3%, including 17.8% CR. The median DOR was 25.6 months. The median PFS was 12.3 months, and the median OS was not reached, with an OS rate at 24 months of 56.3% (Friedlander et al., 2021). The most common treatment-related adverse events were peripheral sensory neuropathy (56%, 4% grade ≥ 3), fatigue (51%, 11% grade ≥ 3), and alopecia (49%) (Rosenberg et al., 2020).

Due to these results, the pivotal phase III EV-302 trial is underway. This trial originally compared EV plus pembrolizumab versus GC/CbG versus EV plus pembrolizumab and cisplatin or carboplatin as first-line treatment for advanced or mUC (NCT04223856). The enrollment of the third arm was discontinued in August 2020. The primary endpoints are PFS and OS.

Other ongoing studies include combinations of CPI with targeted therapies in randomized phase II trials like the NORSE trial (NCT03473743) of erdafitinib or erdafitinib plus cetrelimab for patients with *FGFR* alterations; the FORT-2 trial (NCT03473756) of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with *FGFR* alterations; or the FIGHT-205 trial (NCT04003610) of pemigatinib or pemigatinib plus pembrolizumab for cisplatin ineligible patients with *FGFR3* mutation or rearrangement, among others. The phase III trial LEAP-011 trial (NCT03898180) of lenvatinib and pembrolizumab combination in patients ineligible for platinum-based CT has been recently discontinued for futility (NCT03898180 Cg, 2022).

2.2. Comparing different novel first-line therapeutic approaches

Although the role of platinum-based CT remains a critical option in advanced UC, its administration partially depends on the presence or absence of medical comorbidities and the criteria for eligibility proposed by Galsky et al. (2011). It is well recognized that the use of cisplatin is associated with OS benefit and eligible patients not treated with cisplatin had a shorter median OS (Bamias et al., 2018). In addition, for patients who are ineligible for standard cisplatin-based CT, pembrolizumab and atezolizumab are alternative choices in EU for patients with high PD-L1 expression providing an alternative to carboplatin-based CT (Food and Drug Administration, 2022b; European Medicines Agency, 2022), although randomized trials have failed to show significant superiority compared with CT (Galsky et al., 2020; Powles et al., 2021).

Results from first-line chemo-immunotherapy trials in patients with mUC were recently published with disappointing results, suggesting that

monotherapy with a CPI in first-line is not the optimal approach in the majority of patients (Galsky et al., 2020; Powles et al., 2021). The therapeutic strategy that seems to have provided the greatest robustness in terms of efficacy correspond to avelumab as first-line maintenance therapy in patients whose disease has not progressed with first-line platinum-based CT, based on the results of the JAVELIN Bladder 100 trial (Powles et al., 2020). Rapid introduction of post-platinum switch maintenance therapy with avelumab is the preferred option over treatment break since it delays disease progression and has shown a benefit in OS, with the longest OS ever achieved in a trial for patients with mUC. This strategy does not require PD-L1 testing for assessing eligibility for avelumab as the benefit is observed regardless PD-L1 status. Therefore, in line with the recent updated ESMO and NCCN guidelines, platinum-eligibility should guide therapeutic decisions in first-line advanced UC and platinum-based CT followed by maintenance avelumab is recommended and preferential compared with upfront CPI monotherapy in cisplatin-ineligible PD-L1 positive patients (Powles et al., 2020; NCCN Guidelines®, 2021; Powles et al., 2021; Food and Drug Administration, 2022c; Inacio, 2022). The recent FDA label change for pembrolizumab reinforces the idea that for cisplatin-ineligible PD-L1 positive patients, CbG followed by avelumab maintenance is the preferred option instead of pembrolizumab upfront. First-line treatment with CPI monotherapy could be limited to patients who are platinum-ineligible, have high PD-L1 expression and specific clinical characteristics (Table 2). Recent FDA label for pembrolizumab restricts its use to platinum ineligible without the need of testing for PD-L1 (Food and Drug Administration, 2021). Finally, ADCs targeting a highly expressed tumor protein and conjugated to a CT payload, such as for EV or SG, are emerging as effective therapies for subsequent lines of treatment. EV is being developed in a phase III in the upfront setting based on the promising results from the phase I/II EV-103 study of EV in combination with pembrolizumab (Rosenberg et al., 2020; Friedlander et al., 2021).

2.3. Second and later lines of treatment

A significant proportion of mUC patients do not receive second-line therapy due to deterioration or other comorbidities. For patients who receive second-line therapy, survival is progressively worse (Flannery et al., 2019; Simeone et al., 2019). Patients with mUC who have progressed on first-line treatment with platinum-based CT may choose to be treated with different drugs. Traditionally, they have been treated with CT based on vinflunine or taxanes (McCaffrey et al., 1997; Vaughn et al., 2002; Joly et al., 2009; Petrylak et al., 2017; Gómez de Liaño and Durán, 2018; de Santis et al., 2009; Sonpavde et al., 2016). Vinflunine showed an improvement in terms of survival compared to BSC in the eligible population analysis in a phase III study, while the efficacy of treatment with taxanes was derived from phase II studies (Gómez de Liaño and Durán, 2018; de Santis et al., 2009).

The good results obtained subsequently with anti-PD-L1/PD-1 drugs led to the approval of 5 different drugs: durvalumab, nivolumab, and avelumab (based on phase II studies) and atezolizumab and pembrolizumab (based on phase III comparative studies to standard CT) (Plimack et al., 2017; Sharma et al., 2017; Rosenberg et al., 2016; Massard et al., 2016; Sharma et al., 2016; Apolo et al., 2017; Bellmunt et al., 2017). The ORR obtained with the different drugs ranged between 13% and 24%, with a PFS between 1.5 and 2.8 months, and an OS between 7.7 and 10.3 months. The only phase III study that clearly demonstrated a statistically significant improvement in the OS was KEYNOTE-045, which randomly assigned 542 patients with advanced UC that recurred or progressed after platinum-based CT to receive pembrolizumab versus the investigator's choice of CT with paclitaxel, docetaxel, and vinflunine. With a median follow-up of 5 years, median OS was 10.1 months vs. 7.2 months; (HR 0.71; 95% CI 0.59–0.86). OS rates at 48 months were 16.7% for pembrolizumab and 10.1% for CT (Bellmunt et al., 2017). In addition, the ORR was higher in patients who

Table 2
Comparison between chemotherapy plus immunotherapy trials (KEYNOTE-361 and IMvigor130) and immunotherapy trial DANUBE.

Strategy	Chemotherapy plus immunotherapy				Immunotherapy	
	KEYNOTE-361 (Powles et al., 2021)		IMvigor130 (Galsky et al., 2020)		DANUBE (Powles et al., 2020)	
N	1010		1213		~885	
Trial design	Open label		Double blinded		Open label	
Arms	Pembro + GC/CbG (CT) (A) Pembro (B) CT (C)		Atezo + CT (A) Atezo (B) Placebo + CT (C)		Durva + treme (A) Durva (B) CT (C)	
Primary endpoints	PFS, OS (ITT) A vs. C		PFS, OS (ITT) A vs. C OS (ITT) B vs. C only formally tested if above OS is positive		OS (ITT) A vs. C OS (PD-L1 high) B vs. C	
Patient characteristics	Platinum eligible 47% PD-L1 + Pembro+CT vs. CT		Platinum eligible 24% PD-L1 + Atezo+CT vs. CT+placebo		Platinum eligible 60% PD-L1 + Durva+treme vs. CT	
mOS	ITT = 17 vs. 14.3 mo, HR 0.86 not sig (±)	ITT = 15.6 vs. 14.3 mo, HR 0.92 not sig PD-L1 high = 16.1 vs. 15.2 mo, HR 1.01 not sig	2IA mOS (ITT) = 16.1 vs. 13.4 mo, HR 0.84 not sig (±)	Atezo vs. CT+placebo IA mOS (ITT) = 15.7 vs. 13.1 mo, HR 1.02 Interim mOS (PD-L1 +) = NE vs. 17.8 mo, HR 0.68 (#)	ITT = 15.1 vs. 12.1 mo, HR 0.85 not sig (±) PD-L1 high = 17.9 vs. 12.1 mo, HR 0.74 sig	ITT = 13.2 vs. 12.1 mo, HR 0.99 not sig PD-L1 high = 14.4 vs. 12.1 months, HR 0.89 not sig (±)
mPFS	ITT = 8.3 vs. 7.1 mo, HR 0.78 not sig (±)	3.9 vs. 7.1 mo HR 1.32 sig	ITT = 8.2 vs. 6.3 mo, HR 0.82 sig (±)	ITT = 8.2 vs. 6.3 mo, HR 0.82 PD-L1 high = NE, HR 0.68	ITT = 3.7 vs. 6.7 mo PD-L1 high = 4.1 vs. 5.8 mo	ITT = 2.3 vs. 6.7 mo PD-L1 high = 2.4 vs. 5.8 mo
ORR	ITT = 54.7% vs. 44.9% not sig	ITT = 30.3% vs. 44.9% not sig	ITT = 47% vs. 44% not sig	ITT = 23% vs. 44%	ITT = 36% vs. 49% PD-L1 high = 47% vs. 48%	ITT = 26% vs. 49% PD-L1 high = 28% vs. 48%
Second-line	Pembro + CT	Pembro CT	Atezo + CT	Atezo CT + placebo	Durva + Treme	Durva CT
Subsequent treatment	35.3%	41% 61.6%	26.2%	39.8% 41%	45%	47% 54%
Immunotherapy	6.6%	4.6% 48%	4.6%	2.6% 20.4%	5%	3% 31%

(#) Not formally tested. (±) primary endpoint.

2IA: second interim analysis; Atezo: atezolizumab; C: cisplatin; Cb: carboplatin; CT: chemotherapy; Durva: durvalumab; G: gemcitabine; IA: interim analysis; ITT: intention-to-treat; m: median; mo: month; PD-L1: programmed death-ligand 1; Pembro: pembrolizumab; PFS: progression-free survival; sig: statistically significant; Treme: tremelimumab; ORR: objective response ratio; OS: overall survival.

received pembrolizumab (21.9% vs. 11%) and median DOR for responders was longer for pembrolizumab vs. CT (29.7 months vs. 4.4 months) (Bellmunt et al., 2017; Bellmunt et al., 2021). The second study, the IMvigor211, which randomly assigned 931 patients to atezolizumab or CT, failed to achieve its primary objective of improving survival in the IC2/3 population (n = 234) in a hierarchical design (median 11.1 months vs. 10.6 months (HR 0.87; 95% CI 0.63–1.21), thus precluding further formal statistical analysis. Despite this, atezolizumab maintained its approval for second-line use (Powles et al., 2018). More recently, the accelerated approvals of atezolizumab and durvalumab were voluntarily withdrawn by the responsible companies in the United States following the failure of the confirmatory phase III trials (IMvigor211 and DANUBE) (Powles et al., 2018; Powles et al., 2020; Slater, 2022; Sternberg, 2022).

In addition to immunotherapy treatments, other new drugs are being developed. Those directed against FGFR, such as erdafitinib, have achieved an ORR of 40% in a phase II study of patients with mUC and FGFR genetic alterations after treatment with platinum-based CT and, in many cases, after treatment with CPI (Loriot et al., 2019). Among the 22 patients who had previously received immunotherapy, the ORR was 59% (Loriot et al., 2019). In 2019, the FDA granted accelerated approval for erdafitinib in patients with locally advanced or mUC, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing CT, including within 12 months of neoadjuvant or adjuvant platinum-containing CT (Food and Drug Administration, 2022d). A randomized phase III clinical trial to evaluate efficacy of erdafitinib versus vinflunine, docetaxel or pembrolizumab (based on prior CPI treatment) in patients with mUC harboring selected

FGFR aberrations who have progressed after 1 or 2 prior treatments, is currently ongoing, and its results will refine the role of erdafitinib in these patient populations (NCT03390504).

Additionally, several other drugs targeting the FGF-FGFR signaling pathway, including small molecule FGFR tyrosine kinase inhibitors, FGFR antibodies, FGF ligand traps, and ADCs are being actively tested in mUC in first and subsequent lines both as single agents or in combinations (Garje et al., 2020).

ADC therapies such as EV have shown efficacy in pretreated patients with locally advanced or metastatic disease. The phase III trial EV-301 randomly assigned 608 patients who had previously received platinum-containing CT and whose disease had progressed during or after treatment with an anti-PD-L1/PD-1 to receive EV or investigator of choice CT (taxanes or vinflunine) (Powles et al., 2021). At the pre-specified interim analysis, the median follow-up was 11.1 months. The primary OS endpoint was longer in the EV group than in the CT group (median OS 12.88 vs. 8.97 months; HR 0.70; 95% CI 0.56–0.89). PFS was also longer in the EV group than in the CT group (median PFS 5.55 vs. 3.71 months; HR 0.62; 95% CI 0.51–0.75). ORR was also significantly higher in the EV arm (40.6% vs. 17.9%, of which 4.9% and 2.7% were CR, respectively). The incidence of treatment-related adverse events was similar in the two groups as well as the incidence of events of grade ≥ 3 (Powles et al., 2021). Patients receiving EV had numerically less deterioration and variability in quality of life during the first 12 weeks of treatment than patients in the CT group (Mamtani et al., 2021). Additionally, the results from the cohort 2 of the phase II study EV-201, which included 89 patients with locally advanced or mUC with progression on a prior CPI in the upfront setting, showed an ORR of 52%

with 20% CR and a median DOR of 10.9 months. Median PFS and OS were 5.8 months and 14.7 months, respectively (Yu et al., 2021). In July 2021, the FDA granted regular approval for EV based on the results of the above studies, for adult patients with locally advanced or mUC who have previously received a PD-L1/PD-1 inhibitor and platinum-containing CT or are ineligible for cisplatin-containing CT and have previously received one or more prior lines of therapy (Food and Drug Administration, 2022e).

Another ADC is SG, a Trop-2-directed ADC to a topoisomerase I inhibitor (SN-38). Data from the cohort 1 of the phase II TROPHY-U-01 study, which included 113 patients with mUC previously treated with platinum-based CT and anti-PD-L1/PD-1 therapy, showed an ORR of 27% (5% had CR). The median PFS was 5.4 months, and the median OS was 10.5 months (Loriot et al., 2020). TROPiCS-04 is an ongoing phase II multicenter, open-label, randomized, controlled trial in patients with locally advanced unresectable or mUC who progressed after prior platinum-based and CPI therapies. Approximately 482 patients will be randomized to receive SG or CT of choice (Grivas et al., 2021). In April 2021, the FDA granted accelerated approval for SG in patients with locally advanced or mUC who previously received a platinum-containing CT and either a PD-L1/PD-1 inhibitor (Food and Drug Administration, 2022f). Table 3 shows a summary of the efficacy data for all these treatments.

3. Molecular and genetic markers

In the current treatment scenario of mUC with different drugs recently approved, the identification of valid predictive biomarkers remains of paramount importance to maximize treatment benefit and minimize detrimental effects.

3.1. Predictive biomarkers for checkpoint inhibitors

PD-L1 protein expression in either tumor or immune cells was proposed early on as a potential biomarker of response to CPIs based on the mechanisms of action of these drugs. More than 80% of the CPI pivotal trials in different tumors had PD-L1 expression as a correlate. However, only 28.9% of the 45 studies confirmed a predictive role for PD-L1 and 9 FDA regulatory approvals required companion PD-L1 diagnostic testing (Davis and Patel, 2019).

In mUC, the predictive value of PD-L1 expression has been inconsistent. In platinum-refractory patients, higher levels of PD-L1 in infiltrating immune cells correlated with better ORR in early studies with atezolizumab (Rosenberg et al., 2016; Powles et al., 2014). However, in a confirmatory phase III trial (IMvigor211), high PD-L1 expression did not predict greater benefit of atezolizumab versus CT (Powles et al., 2018). Likewise, the initial development of pembrolizumab focused on mUC with PD-L1 expression $\geq 1\%$ in tumor cells or stroma (Plimack

et al., 2017), however the pivotal randomized phase III trial in mUC platinum-refractory patients (KEYNOTE-045) showed pembrolizumab OS benefit when compared to CT irrespective of PD-L1 status (Bellmunt et al., 2017). Furthermore, atezolizumab and pembrolizumab were initially approved in the frontline setting in cisplatin-ineligible PD-L1-positive patients. An exploratory analysis of the confirmatory phase III trial IMvigor130 suggested an improved OS with atezolizumab monotherapy versus CT in cisplatin-ineligible patients PD-L1-positive (Galsky et al., 2021). Conversely, a similar analysis in the KEYNOTE-361 trial suggested that PD-L1 CPS did not predict outcome with pembrolizumab in cisplatin-ineligible patients (Powles et al., 2021), leading the FDA to modify the present label for pembrolizumab, limiting it to platinum ineligible patients independently of PD-L1 expression.

In the phase III JAVELIN Bladder 100 study, avelumab maintenance benefited patients regardless PD-L1 biomarker (40). Furthermore, several exploratory biomarkers were evaluated including PD-L1, tumor mutational burden (TMB), mutation profile, and genetic signatures (Powles et al., 2020). The PD-L1-positive population was investigated as a co-primary endpoint in a pre-specified analysis and revealed a potentially greater benefit for PD-L1 expressing patients (HR 0.56 vs. 0.69 in the entire population). Nevertheless, PD-L1 expression was associated with survival irrespective to the treatment arm and since it was not a stratification factor, further conclusions cannot be reached, remaining elusive the prognostic value of PD-L1 in this setting. Further analyses also suggest that PD-L1 expression alone did not fully predict OS benefit (Powles et al., 2021). When TMB was analyzed, the median number of non-synonymous mutations (7.66 mutations/Mb) was used to define patient subgroups. Patients with TMB above this threshold showed a greater OS benefit with avelumab despite being PD-L1 negative (HR 0.44). Conversely, tumors with low TMB but PD-L1 positive benefited from avelumab (HR 0.60). Therefore, it may be concluded that neither the biomarkers, TMB nor PD-L1 status individually, are sufficient to properly select patients most likely to benefit from therapy. The type of mutational process (mutational signature) was also analyzed. An apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature that caused a cytosine to thymine transition as well as mutations located in DNA damage response and repair genes, showed greater benefit from avelumab. Furthermore, gene expression analysis showed that a higher expression of immune modulation-related genes related to innate and adaptive effector cells (CD8, CXCL9, IFNG, LAG3, and TIGIT) correlated with better outcomes in patients who received avelumab. Lastly, immune gene signatures previously developed in other tumor types were explored in JAVELIN Bladder 100 patients, which showed some discriminatory capacity and were also able to identify alternative mechanisms of resistance that might involve a network of tumor supporting pathways, such as tumor growth factor beta and angiogenesis (Powles et al., 2021). Whereas no

Table 3
Current treatments for the second-line approach in locally advanced disease.

Drug	Trial	N	Phase	Line	ORR	CRR	OS, months
Docetaxel (McCaffrey et al., 1997; Petrylak et al., 2017)		30	II	≥ 2 nd Line	13%		9
Paclitaxel (Vaughn et al., 2002; Joly et al., 2009)		31	II	2nd Line	10%		7
Vinflunine (de Santis et al., 2009)	V vs. BSC	37	III	2nd Line	9%		6.9
Nivolumab (Sharma et al., 2017; Sharma et al., 2016)	CheckMate 032	78	I/II	≥ 2 nd Line	24%	6%	9.7
	CheckMate 275	270	II	2nd Line	20%	3%	8.6
Atezolizumab (Rosenberg et al., 2016; Powles et al., 2018)	IMvigor210	310	II	≥ 2 nd Line	16%	7%	7.9
	IMvigor211		III vs. CT	≥ 2 nd Line	13%	3%	8.6
Pembrolizumab (Plimack et al., 2017; Bellmunt et al., 2017)	KEYNOTE-012	27	II	≥ 2 nd Line	26%	11%	13
	KEYNOTE-045	542	III vs. CT	≥ 2 nd Line	21.1%	8%	10.3
Durvalumab (Massard et al., 2016)	MED14736	41	I	≥ 2 nd Line	31%		NR
Avelumab (Apolo et al., 2017)	JAVELIN Solid Tumor	249	II	≥ 2 nd Line	16%	5%	7.7
Erdafitinib (Loriot et al., 2019)	BLC2001	99	II	≥ 2 nd Line	40%	3%	13.8
Enfortumab vedotin (Powles et al., 2021)	EV301	608	III	3rd Line	40.6%	4.9%	12.9
Sacituzumab govitecan (Loriot et al., 2020)	TROPHY-U01	113	II	3rd Line	27%	5%	10.5

BSC: best supportive care; CRR: complete response rate; CT: chemotherapy; OS: overall survival; ORR: objective response rate.

molecular biomarker has been validated to predict benefit from avelumab maintenance until now, candidate patients were selected by no progression on prior platinum-based CT, which has been proposed as a putative clinical marker to identify a group of patients who may benefit from avelumab maintenance (Grivas et al., 2021). More recently, The Cancer Genome Atlas (TCGA) genomic subgroups have been evaluated as potential predictors of benefit in a post-hoc analysis of JAVELIN Bladder 100 trial. The survival benefit for avelumab was apparent across TCGA subtypes except luminal. Yet, the small sample size and the wide CI limit any practical conclusion (Powles et al., 2021).

3.2. Biomarkers to other targeted agents

EV and SG are ADCs that bind proteins Nectin-4 and Trop-2 respectively, which have been reported to be widely expressed in UC both in bladder cancer and upper genitourinary tract tumors and therefore no prior testing would be necessary (Stepan et al., 2011; Challita-Eid et al., 2016; Rosenberg et al., 2020). Heterogeneity of expression of Nectin-4, Trop-2, and other targets has been reported in variant histologies (i.e. small cell, carcinosarcoma, etc.) with low or null expression and this may have therapeutic implications (Hoffman-Censits et al., 2020). Nectin-4 and Trop-2 expression have been confirmed as negative prognostic biomarkers in several tumors, including UC (Tomiyama et al., 2020).

FGFR could probably be considered the only fully validated predictive biomarker in mUC therapeutics as discussed above. *FGFR* presents aberrations in about 15–20% of mUC cases, with these gene abnormalities exceeding 40–50% in upper tract UC (Rodríguez-Vida et al., 2015; Li et al., 2016). Recent data from a mUC biomarker driven study revealed that tumors with *FGFR* alterations had a low prevalence of PD-L1 expression and TMB. Analysis of mRNA expression revealed an increased proportion of the luminal papillary subtype in tumors with *FGFR* alterations but not a higher expression of immune-active T-cell signatures (Powles et al., 2021). These findings might have a potential predictive value although data are still not consistent and require further validation.

4. Current treatment guidelines

NCCN Guidelines Version 5.2021 recommends first-line cisplatin-based CT (GC or ddMVAC with growth factor support in selected patients) followed by avelumab maintenance therapy in those patients not progressing with first-line CT, as the preferred regimen (category 1) (NCCN Guidelines®, 2021). In cisplatin-ineligible patients, preferred regimens are CbG followed by avelumab maintenance therapy (category 1) if there is no progression to first-line CT. Atezolizumab is recommended in cisplatin-ineligible patients only if their tumors express PD-L1 or if they are not eligible for any platinum-containing CT regardless of PD-L1 expression (category 2 A). P(NCCN Guidelines®, 2021).

For second-line systemic therapy in patients who progress on platinum-based CT, the preferred regimen is pembrolizumab (category 1). Alternative preferred regimens include other CPIs (nivolumab or avelumab), erdafitinib or EV (if available) (category 2 A). Other recommended regimens include paclitaxel, docetaxel or gemcitabine (category 2 A). In patients who progress after CPIs, the preferred regimen for cisplatin-ineligible and CT-naïve patients is CbG or EV if available (Yu et al., 2021), and for cisplatin-eligible CT naïve patients it is GC or ddMVAC with growth factor support (category 2 A) (NCCN Guidelines®, 2021). For the next line of systemic therapy in locally advanced or metastatic disease, the preferred regimen is EV (category 1) or erdafitinib in patients with susceptible *FGFR3* or *FGFR2* genetic alterations (category 2 A) (NCCN Guidelines®, 2021).

In the ESMO guidelines, platinum-based CT is recommended for advanced or mUC (I, A). GC or CbG are the most widely used regimens. In patients who have not progressed following 4–6 cycles of first-line

platinum-based CT, maintenance avelumab started within 10 weeks maximum of completion of CT is recommended (I, A; MCBS 4). Pembrolizumab or atezolizumab are alternative choices for the first-line in cisplatin-ineligible metastatic patients who are PD-L1-positive (III, B) (Powles et al., 2021). Platinum-based CT followed by maintenance avelumab is preferential compared with upfront CPIs in PD-L1 biomarker-positive patients. No consensus could be reached for CPIs in PD-L1 biomarker-negative patients not eligible for any CT (Powles et al., 2021).

In patients with platinum-refractory disease CPIs are standard options: pembrolizumab (I, A; MCBS 4), atezolizumab (II, B), nivolumab (III, B), avelumab (III, C), and durvalumab (III, C). Treatment with CT is an alternative for patients in whom CPIs are not possible. Vinflunine (II, C), docetaxel (III, C), and paclitaxel (III, C) can be considered. Combinations with taxanes may be considered as an option only in selected patients. Erdafitinib (not currently EMA-approved) is an option in platinum-refractory or platinum- and CPI-refractory UC tumors with selected *FGFR2* or *FGFR3* alterations (III, B). EV is recommended in patients with platinum- and CPI-refractory UC (I, A; MCBS 4) or after relapse to first-line CPI (III, B) as alternative to CT (Powles et al., 2021).

The European Association of Urology (EAU) guidelines, published in September 2021, are in agreement with the above ESMO guidelines (Cathomas et al., 2022).

5. Proposal for a new treatment algorithm for patients with metastatic urothelial carcinoma

Based on the current evidence, the different therapeutic options for the treatment of patients with UC are summarized in Fig. 2. Due to the continuous advances in diagnosis, surgical techniques, radiotherapy, medical treatments and clinical trials, a multidisciplinary approach is recommended to design the most appropriate strategy for every patient, taking into consideration the stage of the disease, the comorbidities and circumstances of the patient, and the resources available in each center.

6. Questions remaining for the future

Avelumab first-line maintenance is the new SoC in patients with no progression on platinum-based CT regardless of PD-L1 status. Despite the improvement in OS and PFS shown in the JAVELIN Bladder 100 trial, 37% of patients had disease progression as best response in the avelumab plus BSC arm. Novel therapeutic approaches combining avelumab with other drugs in the first-line maintenance setting are under development (TALASUR study with talazoparib/NCT04678362; MAIN-CAV study with cabozantinib/NCT05092958; PRESERVE3 study with trilaciclib/NCT04887831) to further improve the benefit seen in the JAVELIN Bladder 100 trial. Longer follow-up and additional analysis may provide some information and help to identify those patient populations who benefit the most from avelumab maintenance. Furthermore, it remains questioned whether avelumab maintenance may be an option for patients with no progression on less than the 4 platinum-based CT cycles (i.e. ≤ 3 cycles) in the first-line setting. The findings from the DISCUS trial will provide some clarity on this regard (Powles, 2022). Clinical data with avelumab maintenance after prior CPIs in the neoadjuvant or adjuvant setting will be interesting to have in the face of the arrival of CPIs into the perioperative setting. Another scenario where no data are available with CPI maintenance is in the second-line setting after CR, PR, or SD with a platinum-based CT after progression on frontline CPI monotherapy. The treatment sequence after progression on avelumab maintenance also remains to be clarified; based on the information of subsequent lines from the JAVELIN Bladder 100 trial, CT, platinum-based CT rechallenge and targeted therapies can be used (Grivas et al., 2021). EV and erdafitinib are reasonable alternatives as they have already shown efficacy in mUC after progression to platinum-based CT and/or CPI monotherapy and have also been used as a subsequent line of therapy after progression on avelumab maintenance




Fig. 2. Therapeutic options and comprehensive approach for the patient with bladder carcinoma. ACT: adjuvant chemotherapy; BCG: Bacillus Calmette-Guérin; CR: complete response; CT: chemotherapy; CPI: immune checkpoints inhibitors; IT: immunotherapy; NACT: neoadjuvant chemotherapy; NMIBC: non-muscle invasive bladder carcinoma; MIBC: muscle invasive bladder carcinoma; Mito-C: Mitomycin C; PFI: platinum-free interval; PR: partial response; SD: stable disease; TURBT: transurethral resection of bladder tumor. 1. Licensed by FDA for BCG-unresponsive NMIBC patients; 2. For patients who have not received neoadjuvant chemotherapy; 3. Nivolumab has been licensed by FDA as adjuvant therapy for MIBC in patients who had pT2-pT4 or pN+ after NACT, or pT3-4a or pN+ after cystectomy without previous NACT, and refuse, or are not eligible for ACT; 4. Pembrolizumab and atezolizumab have been approved by FDA and EMA for patients with PDL1 + expression (see text for details) and may be an option for patients unable to receive CT (pembrolizumab recently restricted by FDA for patients unable to receive CT); 5. Nivolumab and atezolizumab are also approved by EMA, and nivolumab and avelumab by FDA for second-line after platinum-based CT. No data available in patients with prior CPI; 6. FDA and EMA approved; 7. FDA approved; 8. FDA approved in patients with altered FGFR. See text for further details and references.

in the pivotal trial.

7. Summary

- With the aim of bringing treatment with immunotherapy into earlier lines and offer these active therapies to more patients with advanced UC, different therapeutic approaches have been developed in the upfront setting, including the use of CPIs as single agents, combinations of CPIs ± CT or ADC and the use of CPIs as maintenance after non-progression with first-line CT.
- The phase III JAVELIN Bladder 100 trial was designed with the aim of extending the initial benefit achieved with first-line platinum-based CT by adding avelumab maintenance in patients that had not progressed to CT.
- According to the NCCN, ESMO and EAU treatment guidelines, rapid introduction of avelumab maintenance in patients that have not progressed with platinum-based CT is a preferred option over a treatment break or treatment with a CPI in second-line since it has shown a statistically significant improvement in OS versus BSC, with the longest OS ever achieved in a phase III trial in mUC, and may also enable more patients to receive a CPI rather than reserving it to the second-line. Avelumab maintenance does not require PD-L1 testing for treatment selection as the benefit is observed regardless of PD-L1 status. Based on single-arm phase II trials, first-line treatment with atezolizumab or pembrolizumab are alternatively choices in Europe only for cisplatin-ineligible patients with PD-L1 positive tumors or if they are not eligible for any platinum-containing CT (FDA only).
- Unlike other solid tumors such as lung cancer, currently there is no evidence supporting the use of the combination of CPIs and CT as first-line therapy in mUC and this strategy is not currently recommended. First-line phase III chemo-immunotherapy trials (IMvigor130 and KEYNOTE-361) have recently been published with disappointing results.

- ADCs such as EV and SG, which target specific proteins expressed in UC cells, have shown promising activity as single agent in subsequent lines of treatment. Moreover, the combination of EV with pembrolizumab is being currently tested in a randomized phase III study in the upfront setting (EV-302 trial) based on the remarkable activity from the phase I/II trial (EV-103 study).

Funding

Medical writing support was provided by HealthCo Trials (Madrid, Spain) and was funded by Pfizer as part of an alliance between Pfizer and Merck (CrossRef Funder ID: 10.13039/100009945). J.B., B.P.V., J.P., E. G., N.L., S.V., P.M., M.A.C., X.G.M., J.A.A., and I.D. received honoraria from Pfizer for writing and reviewing the manuscript.

Acknowledgements

The authors are grateful for the editorial assistance of Fernando Sánchez Barbero of HealthCo Trials (Madrid, Spain) in the production of this manuscript and for the writing and review of Belén Sanz Castillo of Pfizer SLU (Madrid, Spain). This article is a non-systematic review of published literature and does not contain any original study with human participants or animals performed by any of the authors.

Conflict of Interest Statement

Dr. Joaquim Bellmunt has received honoraria from AstraZeneca, Bristol-Myers Squibb, Merck, MSD, Pfizer, Pierre Fabre and Takeda Pharmaceutical Company; consultancy or advisory roles from AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Pierre Fabre and Hoffmann-La Roche; research funding from Pfizer and Takeda Pharmaceutical Company; travel and accommodations expenses from Pfizer; licensing and royalties from UpToDate Inc.

Dr. Begoña P. Valderrama has received honoraria for consultancy or advisory roles from Astellas Pharma, Bristol-Myers Squibb, EUSA

Pharma, Hoffmann-La Roche, Ipsen Pharma, MSD, Novartis, Pfizer, Pierre Fabre and Sanofi; speaker engagements from Astellas Pharma, Bayer, Bristol-Myers Squibb, EUSA Pharma, Hoffmann-La Roche, Ipsen Pharma, Novartis and Pierre Fabre; travel and accommodations expenses from Astellas Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Ipsen Pharma and Pfizer.

Dr. Javier Puente has received honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai Co., EUSA Pharma, Hoffmann-La Roche, Ipsen Pharma, Janssen-Cilag, MSD, Pfizer, Pierre Fabre and Sanofi; consultancy or advisory roles from Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis Oncology, Eisai Co., Hoffmann-La Roche, Ipsen Pharma, Janssen-Cilag, MSD, Pfizer and Sanofi; research funding from Astellas Pharma and Pfizer; travel and accommodations expenses from Bristol-Myers Squibb, Hoffmann-La Roche, Janssen-Cilag, MSD and Pfizer.

Dr. Enrique Grande has received honoraria for consultancy and advisory roles, speaker engagements, research funding of continuous medical education from Advanced Accelerator Applications USA, Inc., Amgen Inc., Angelini Pharma, Astellas Pharma, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Caris Life Sciences, Celgene, Clovis Oncology, Eisai Co., Eli Lilly and Company, EUSA Pharma, Genetracer Biotech, Guardant Health, Hoffmann-La Roche, HRA Pharma, Ipsen Pharma, ITM Isotopen Technologien Muenchen AG, Janssen-Cilag, Lexicon, Merck, MSD, NanoString Technologies Inc., Natera Inc., Novartis, OncoDNA, Palex Medical, PharmaMar, Pierre Fabre, Pfizer, Sanofi, Servier Laboratories, Taiho Pharmaceutical Co., and Thermo Fisher Scientific. Dr. Enrique Grande has received research grants from Astellas Pharma, AstraZeneca, Lexicon Pharmaceuticals and Pfizer.

Dr. M. Victoria Bolós is a Pfizer employee.

Dr. Nuria Lainez has received honoraria for consultancy or advisory roles from AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Ipsen Pharma, Pfizer and Sanofi; speaker engagements from Hoffmann-La Roche, Ipsen Pharma, Pfizer and Sanofi; travel and accommodations expenses from Hoffmann-La Roche, Sanofi and Pfizer.

Dr. Sergio Vázquez has received honoraria for consultancy or advisory roles from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, C.H. Boehringer Sohn A.G. & Ko. KG, Eisai Co., EUSA Pharma, Hoffmann-La Roche, Ipsen Pharma, Janssen-Cilag, MSD, Novartis, Pfizer and Sanofi; speaker engagements from Astellas Pharma, AstraZeneca, C. H. Boehringer Sohn A.G. & Ko. KG, Eli Lilly and Company, Hoffmann-La Roche, Ipsen Pharma, Novartis and Sanofi; travel and accommodations expenses from AstraZeneca, Hoffmann-La Roche and Pfizer.

Dr. Pablo Maroto has received honoraria for consultancy or advisory roles from Pfizer, Astellas Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Ipsen Pharma, Janssen-Cilag and Pfizer; speaker engagements from Astellas Pharma, Bayer, Hoffmann-La Roche, MSD, Novartis and Pfizer; research grants from Astellas Pharma and Hoffmann-La Roche; travel and accommodations expenses from Ipsen Pharma.

Dr. Miguel Ángel Climent has received honoraria from Astellas Pharma, Bayer, Bristol-Myers Squibb, Hoffmann-La Roche, Ipsen Pharma, Janssen-Cilag, MSD, Novartis, Pfizer and Sanofi; travel and accommodations expenses from Astellas Pharma, Hoffmann-La Roche, Ipsen Pharma, Janssen-Cilag and MSD.

Dr. Xavier García del Muro has received honoraria for consultancy or advisory roles from Bristol-Myers Squibb, Eli Lilly and Company, EUSA Pharma, GlaxoSmithKline, Hoffmann-La Roche, Ipsen Pharma, PharmaMar and Pfizer; speaker engagements from Astellas Pharma, Bristol-Myers Squibb, Eisai Co. and Pfizer; research funding from AstraZeneca; travel and accommodations expenses from Hoffmann-La Roche and Pfizer.

Dr. José Ángel Arranz has received honoraria from Astellas Pharma, Bristol-Myers Squibb and Pfizer; consultancy or advisory roles from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen-Cilag, Merck, MSD and Pfizer; research funding from Bristol-Myers Squibb.

Dr. Ignacio Durán has received honoraria for consultancy or advisory roles from Astellas Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Immunomedics Inc., Ipsen Pharma, Merck and MSD; speaker engagements from Astellas Pharma, Bristol-Myers Squibb, EUSA Pharma, Ipsen Pharma, Janssen-Cilag, MSD, Novartis and Pfizer; research funding from AstraZeneca; research grants from AstraZeneca and Hoffmann-La Roche; travel and accommodations expenses from Hoffmann-La Roche and Pfizer; Ignacio Durán is a member of a SC for a trial sponsored by Immunomedics Inc., a member of Board Directors of ASEICA as an external advisor to the board of directors of the Spanish Association of cancer research and the president of GO NORTE, an independent cooperative group of GU Oncologist from the north of Spain.

References

- Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, 2005. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. *Eur. Urol.* 48 (2), 202–205.
- Aly, A., Johnson, C., Yang, S., Botteman, M.F., Rao, S., Hussain, A., 2019. Overall survival, costs, and healthcare resource use by line of therapy in medicare patients with newly diagnosed metastatic urothelial carcinoma. *J. Med. Econ.* 22 (7), 662–670. <https://doi.org/10.1080/13696998.2019.1591424>.
- Apolo, A.B., Infante, J.R., Balmanoukian, A., Patel, M.R., Wang, D., Kelly, K., et al., 2017. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase II study. *J. Clin. Oncol.* 35 (19), 2117–2124. <https://doi.org/10.1200/JCO.2016.71.6795>.
- Bajorin, D.F., 2016. Chapter 197 - tumors of the kidney, bladder, ureters, and renal pelvis. In: Goldman, L., Schafer, A.I. (Eds.), *Goldman-Cecil Medicine, twentyfifth ed. Elsevier Saunders, Philadelphia*, pp. 1348–1351.
- Bajorin, D.F., Witjes, J.A., Gschwend, J.E., Schenker, M., Valderrama, B.P., Tomita, Y., et al., 2021. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. *New Engl. J. Med.* 384 (22), 2102–2114. <https://doi.org/10.1056/NEJMoa2034442>.
- Balar, A.V., Galsky, M.D., Rosenberg, J.E., Powles, T., Petrylak, D.P., Bellmunt, J., et al., 2017. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet* 389 (10064), 67–76. [https://doi.org/10.1016/S0140-6736\(16\)32455-2](https://doi.org/10.1016/S0140-6736(16)32455-2).
- Balar, A.V., Castellano, D., O'Donnell, P.H., Grivas, P., Vuky, J., Powles, T., et al., 2017. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. *Lancet Oncol.* 18 (11), 1483–1492. [https://doi.org/10.1016/S1470-2045\(17\)30616-2](https://doi.org/10.1016/S1470-2045(17)30616-2).
- Balar, A.V., Dreicer, R., Loriot, Y., Pérez-Gracia, J.L., Hoffman-Censits, J., Petrylak, D.P., et al., 2018. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. *J. Clin. Oncol.* 36 (15 Suppl) https://doi.org/10.1200/JCO.2018.36.15_suppl.4523.
- Balar, A.V., McGregor, B.A., Rosenberg, J., van der Heijden, M.S., Park, S.H., Lee, J.L., et al., 2021. EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. *J. Clin. Oncol.* 39 (6 Suppl) https://doi.org/10.1200/JCO.2021.39.6_suppl.394.
- Balar, A.V., Kamat, A.M., Kulkarni, G.S., Uchio, E.M., Boormans, J.L., Roumiguié, M., et al., 2021. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. *Lancet Oncol.* 22 (7), 919–930. [https://doi.org/10.1016/S1470-2045\(21\)00147-9](https://doi.org/10.1016/S1470-2045(21)00147-9).
- Bamias, A., Tzannis, K., Harshman, L.C., Crabb, S.J., Wong, Y.N., Kumar Pal, S., et al., 2018. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). *Ann. Oncol.* 29 (2), 361–369. <https://doi.org/10.1093/annonc/mdx692>.
- Bellmunt, J., von der Maase, H., Mead, G.M., Skoneczna, I., de Santis, M., Daugaard, G., et al., 2012. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. *J. Clin. Oncol.* 30 (10), 1107–1113. <https://doi.org/10.1200/JCO.2011.38.6979>.
- Bellmunt, J., Orsola, A., Leow, J.J., Wiegel, T., De Santis, M., Horwich, A., et al., 2014. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 25 (Suppl 3), iii40–iii48. <https://doi.org/10.1093/annonc/mdl223>.
- Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.L., Fong, L., et al., 2017. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *New Engl. J. Med.* 376 (11), 1015–1026. <https://doi.org/10.1056/NEJMoa1613683>.
- Bellmunt, J., Hussain, M., Gschwend, J.E., Albers, P., Oudard, S., Castellano, D., et al., 2021. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 22 (4), 525–537. [https://doi.org/10.1016/S1470-2045\(21\)00004-8](https://doi.org/10.1016/S1470-2045(21)00004-8).
- Bellmunt, J., Necchi, A., De Wit, R., Lee, J.L., Fong, L., Vogelzang, N., et al., 2021. Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the

- phase 3 KEYNOTE-045 trial. *J Clin Oncol*. 39 (15 Suppl) https://doi.org/10.1200/JCO.2021.39.15_suppl.4532.
- Bellmunt, J., Powles, T., van der Heijden, M.S., Galsky, M.D., He, P., Wang, Z., et al., 2021. 708P - PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC). *Ann. Oncol.* 32 (Suppl 5), S678–S724. <https://doi.org/10.1016/j.annonc.annonc675>.
- Bellmunt Molins, J., García-Donas Jiménez, J., Valderrama, B.P., Virizuela Echaburu, J. A., Hernando-Polo, S., Climent Durán, M.A., et al., 2020. final overall survival analysis of the SOGUG phase 2 MAJA study: maintenance vinflunine versus best supportive care after first-line chemotherapy in advanced urothelial carcinoma. *Clin. Genitourin Cancer* 18 (6), 452–460. <https://doi.org/10.1016/j.clgc.2020.05.004>.
- Bochner, B.H., Hansel, D.E., Efstathiou, J.A., 2017. Urinary bladder. In: Edge, S.B., Greene, F.L., Byrd, D.R. (Eds.), *American Joint Committee on Cancer AJCC Cancer Staging Manual*, eight ed. Springer Publishing, Chicago, IL, pp. 765–774.
- Boorjian, S.A., Alemozaffar, M., Konety, B.R., Shore, N.D., Gomella, L.G., Kamat, A.M., et al., 2021. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. *Lancet Oncol*. 22 (1), 107–117. [https://doi.org/10.1016/S1470-2045\(20\)30540-4](https://doi.org/10.1016/S1470-2045(20)30540-4).
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 68 (6), 394–424. <https://doi.org/10.3322/caac.21492>.
- Buchbinder, E.I., Desai, A., 2016. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. *Am. J. Clin. Oncol.* 39 (1), 98–106. <https://doi.org/10.1097/COC.0000000000002039>.
- Cathomas, R., Lorch, A., Bruins, H.M., Compérat, E.M., Cowan, N.C., Efstathiou, J.A., et al., 2022. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. *Eur. Urol.* 81 (1), 95–103. <https://doi.org/10.1016/j.eururo.2021.09.026>.
- Challita-Eid, P.M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., et al., 2016. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. *Cancer Res.* 76 (10), 3003–3013. <https://doi.org/10.1158/0008-5472.CAN-15-1313>.
- Chau, C.H., Steeg, P.S., Figg, W.D., 2019. Antibody-drug conjugates for cancer. *Lancet* 394 (10200), 793–804. [https://doi.org/10.1016/S0140-6736\(19\)31774-X](https://doi.org/10.1016/S0140-6736(19)31774-X).
- Cheeseman, S., Thompson, M., Sopwith, W., Godden, P., Seshagiri, D., Adedokun, L., et al., 2020. Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre. *Front. Oncol.* 10, 167. <https://doi.org/10.3389/fonc.2020.00167>.
- Davis, A.A., Patel, V.G., 2019. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. *J. Immunother. Cancer* 7 (1), 278. <https://doi.org/10.1186/s40425-019-0768-9>.
- von der Maase, H., Hansen, S.W., Roberts, J.T., Dogliotti, L., Oliver, T., Moore, M.J., et al., 2000. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J. Clin. Oncol.* 18 (17), 3068–3077. <https://doi.org/10.1200/JCO.2000.18.17.3068>.
- von der Maase, H., Sengelov, L., Roberts, J.T., Ricci, S., Dogliotti, L., Oliver, T., et al., 2005. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J. Clin. Oncol.* 23 (21), 4602–4608. <https://doi.org/10.1200/JCO.2005.07.757>.
- Dogliotti, L., Carteni, G., Siena, S., Bertetto, O., Martoni, A., Bono, A., et al., 2007. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. *Eur. Urol.* 52 (1), 134–141. <https://doi.org/10.1016/j.eururo.2006.12.029>.
- Emens, L.A., Middleton, G., 2015. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. *Cancer Immunol. Res.* 3 (5), 436–443. <https://doi.org/10.1158/2326-6066.CIR-15-0064>.
- European Medicines Agency. 2022 Avelumab (Bavencio®): Summary of product characteristics [Available from: https://www.ema.europa.eu/en/documents/product-information/bavencio-epar-product-information_en.pdf].
- European Medicines Agency. 2022 EMA restricts use of Keytruda and Tecentriq in bladder cancer [Available from: <https://www.ema.europa.eu/en/news/ema-restricts-use-keytruda-tecentriq-bladder-cancer>].
- Fisher, M.D., Shenolikar, R., Miller, P.J., Fenton, M., Walker, M.S., 2018. Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015. *Clin. Genitourin Cancer* 16 (6), e1171–e1179. <https://doi.org/10.1016/j.clgc.2018.07.025>.
- Flannery, K., Boyd, M., Black-Shinn, J., Robert, N., Kamat, A.M., 2019. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. *Future Oncol.* 15 (12), 1323–1334. <https://doi.org/10.2217/fon-2018-0654>.
- Food and Drug Administration. {C}2022d{C} FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma [Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma>].
- Food and Drug Administration. 2022a FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer [Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer>].
- Food and Drug Administration. {C}2022c{C} FDA approves avelumab for urothelial carcinoma maintenance treatment [Available from: <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment>].
- Food and Drug Administration. 2022e FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer [Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-enfortumab-vedotin-ejfv-locally-advanced-or-metastatic-urothelial-cancer>].
- Food and Drug Administration. 2022b FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients [Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-limits-use-tecentriq-and-keytruda-some-urothelial-cancer-patients>].
- Food and Drug Administration. 2022f FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer [Available from: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer>].
- Food and Drug Administration. 2019 Enfortumab vedotin prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf).
- Food and Drug Administration. FDA Approves Updated Indication for Merck's KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer) 2021 [Available from: <https://www.merck.com/news/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer/>].
- Friedlander, M., Milowsky, M.L., Bilen, M.A., Srinivas, S., McKay, R.R., Flaig, T.W., et al., 2021. Study EV-103: update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). *J. Clin. Oncol.* 39 (Suppl 15) https://doi.org/10.1200/JCO.2021.39.15_suppl.4528.
- Funt, S.A., Lattanzi, M., Whiting, K., Al-Ahmadie, H.A., Quinlan, C., Teo, M.Y., et al., 2021. Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): a multicenter, single-arm, phase 2 trial. *J. Clin. Oncol.* 39 (15 suppl), 4517. https://doi.org/10.1200/JCO.2021.39.15_suppl.4517.
- Gakis, G., Efstathiou, J., Lerner, S.P., Cookson, M.S., Keegan, K.A., Guru, K.A., et al., 2013. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. *Eur. Urol.* 63 (1), 45–57. <https://doi.org/10.1016/j.eururo.2012.08.009>.
- Galsky, M.D., Hahn, N.M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W.K., et al., 2011. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *J. Clin. Oncol.* 29 (17), 2432–2438. <https://doi.org/10.1200/JCO.2011.34.8433>.
- Galsky, M.D., Pal, S.K., Lin, S.W., Ogale, S., Zivkovic, M., Simpson, J., et al., 2018. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the united states. *Bladder Cancer* 4 (2), 227–238. <https://doi.org/10.3233/BLC-170149>.
- Galsky, M.D., Powles, T., Li, S., Hennicken, D., Sonpavde, G., Less, S., 2018. A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901). *J. Clin. Oncol.* 36 (6 Suppl) https://doi.org/10.1200/JCO.2018.36.6_suppl.TP5539.
- Galsky, M.D., Arijia, J.A.A., Bamias, A., Davis, I.D., de Santis, M., Kikuchi, E., et al., 2020. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet.* 395 (10236), 1547–1557. [https://doi.org/10.1016/S0140-6736\(20\)30230-0](https://doi.org/10.1016/S0140-6736(20)30230-0).
- Galsky, M.D., Mortazzavi, A., Milowsky, M.L., George, S., Gupta, S., Fleming, M.T., et al., 2020. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. *J. Clin. Oncol.* 38 (16), 1797–1806. (<https://doi.org/10.1200/JCO.19.03091>).
- Galsky, M.D., Guan, X., Banchereau, R., Wang, L., Zhu, J., Yu, H., et al., 2021. 658MO - Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC). *Ann. Oncol.* 32 (Suppl 5), S678–S724. <https://doi.org/10.1016/j.annonc/annonc675>.
- Galsky, M.D., Bamias, A., Arranz, J.A., Davis, I.D., De Santis, M., Kikuchi, E., et al., 2021. Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study. *J. Clin. Oncol.* 39 (6 Suppl) https://doi.org/10.1200/JCO.2021.39.6_suppl.434.
- Galsky MD, Arranz JA, Grande E., De Santis M., Davis ID, Kikuchi E., et al., editors. CT042 - Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. AACR Annual Meeting; 2021 April 12nd.
- García-Donas, J., Font, A., Pérez-Valderrama, B., Virizuela, J.A., Climent, M.A., Hernando-Polo, S., et al., 2017. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. *Lancet Oncol.* 18 (5), 672–681a. [https://doi.org/10.1016/S1470-2045\(17\)30242-5](https://doi.org/10.1016/S1470-2045(17)30242-5).
- Garje, R., An, J., Obeidat, M., Kumar, K., Yasin, H.A., Zakharia, Y., 2020. Fibroblast Growth Factor Receptor (FGFR) inhibitors in urothelial cancer. *Oncologist* 25 (11), e1711–e1719. <https://doi.org/10.1634/theoncologist.2020-0334>.

- Gómez de Liaño, A., Durán, I., 2018. The continuing role of chemotherapy in the management of advanced urothelial cancer. *Ther. Adv. Urol.* 10 (12), 455–480. <https://doi.org/10.1177/1756287218814100>.
- Grivas, P., Park, S.H., Voog, E., Caserta, C., Pérez Valderrama, B., Gurney, H., et al., 2020. 704MO - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTX) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100. *Ann. Oncol.* 31 (Suppl 4), S550. <https://doi.org/10.1016/annonc/annonc274>.
- Grivas, P., Park, S.H., Voog, E., Kopytsov, E., Gurney, H., Muniz, D.Q.B., et al., 2021. Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100. *J. Clin. Oncol.* 39 (15 Suppl) <https://doi.org/10.1200/JCO.2021.39.15.suppl.4525>.
- Grivas, P., Tagawa, S.T., Bellmunt, J., De Santis, M., Durán, I., Goebell, P.J., et al., 2021. TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. *J. Clin. Oncol.* 39 (6 Suppl) <https://doi.org/10.1200/JCO.2021.39.6.suppl.TPS498>.
- Grivas, P., Agarwal, N., Pal, S., Kalebastay, A.R., Sridhar, S.S., Smith, J., et al., 2021. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: applying clinical trial findings to clinical practice. *Cancer Treat. Rev.* 97, 102187 <https://doi.org/10.1016/j.ctrv.2021.102187>.
- Grivas, P.D., Daignault, S., Tagawa, S.T., Nanus, D.M., Stadler, W.M., Dreicer, R., et al., 2014. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. *Cancer* 120 (5), 692–701. <https://doi.org/10.1002/ncr.28477>.
- Gupta, S., Sonpavde, G., Weight, C.J., McGregor, B.A., Gupta, S., Maughan, B.L., et al., 2020. Results from BLASS-T-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. *J. Clin. Oncol.* 38 (6 suppl), 439. <https://doi.org/10.1200/JCO.2020.38.6.suppl.439>.
- Harris, S.J., Brown, J., López, J., Yap, T.A., 2016. Immuno-oncology combinations: raising the tail of the survival curve. *Cancer Biol. Med.* 13 (2), 171–193. <https://doi.org/10.20892/j.issn.2095-3941.2016.0015>.
- Hoffman-Censits, J., Choi, W., Lombardo, K., Hahn, N.M., McConkey, D.J., McGuire, B., et al., 2020. Expression of nectin-4 in bladder cancer with variant histology. *J. Clin. Oncol.* 38 (6 Suppl), Abstract 546. (<https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6.suppl.546>).
- Humphrey, P.A., Moch, H., Cubilla, A.L., Ulbright, T.M., Reuter, V.E., 2016. The 2016 WHO classification of tumours of the urinary system and male genital organs - part B: prostate and bladder tumours. *Eur Urol* 70 (1), 106–119. <https://doi.org/10.1016/j.eururo.2016.02.028>.
- Inacio P. 2022 Bavencio approved in EU as first-line maintenance therapy for bladder cancer [<https://immuno-oncologynews.com/2021/01/27/bavencio-approved-eu-first-line-maintenance-therapy-bladder-cancer/?cn-reloaded=1>].
- Joly, F., Houede, N., Noal, S., Chevreau, C., Priou, F., Chinet-Charrot, P., et al., 2009. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. *Clin. Genitourin Cancer* 7 (2), E28–E33. <https://doi.org/10.3816/CGC.2009.n.018>.
- Lee, J.E., Chung, C.U., 2014. Update on the evidence regarding maintenance therapy. *Tuberc Respir Dis* 76 (1), 1–7. <https://doi.org/10.4046/trd.2014.76.1.1>.
- Leow, J.J., Martin-Doyle, W., Rajagopal, P.S., Patel, C.G., Anderson, E.M., Rothman, A. T., et al., 2014. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. *Eur. Urol.* 66 (1), 42–54. <https://doi.org/10.1016/j.eururo.2013.08.033>.
- Li, Q., Bagrodia, A., Cha, E.K., Coleman, J.A., 2016. Prognostic genetic signatures in upper tract urothelial carcinoma. *Curr. Urol. Rep.* 17 (2), 12. <https://doi.org/10.1007/s11934-015-0566-y>.
- Lopez-Beltran, A., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., et al., 2021. Immune checkpoint inhibitors for the Treatment of Bladder Cancer. *Cancers* ((Basel)) 13 (1). <https://doi.org/10.3390/cancers13010131>.
- Loriot, Y., Necchi, A., Park, S.H., García-Donas, J., Huddart, R., Burgess, E., et al., 2019. Erafitinib in locally advanced or metastatic urothelial carcinoma. *New Engl. J. Med.* 381 (4), 338–348. <https://doi.org/10.1056/NEJMoa1817323>.
- Loriot, Y., Balar, A.V., Petrylak, D.P., Tagawa, S.T., Rezazadeh, A., Flechon, A., et al., 2020. LBA24 - TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). *Ann Oncol.* 31 (Suppl 4), S1142–S1215. <https://doi.org/10.1016/annonc/annonc325>.
- Loriot, Y., Powles, T., Climent, M.A., Sridhar, S.S., Bellmunt, J., Petrylak, D.P., et al., 2021. Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. *J. Clin. Oncol.* 39 (6 Suppl) <https://doi.org/10.1200/JCO.2021.39.6.suppl.438>.
- Mamtani, R., Rosenberg, J., Powles, T., Sonpavde, G., Loriot, Y., Durán, I., et al., 2021. Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy. *J. Clin. Oncol.* 39 (Suppl 15) <https://doi.org/10.1200/JCO.2021.39.15.suppl.4539>.
- Martinez Chanza, N., Carnot, A., Barthelemy, P., Casert, V., Sautois, B., Van den Brande, J., et al., 2021. Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC). *Ann. Oncol.* 32 (Suppl 5), S678–S724. <https://doi.org/10.1016/annonc/annonc675>.
- Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., et al., 2016. Safety and efficacy of durvalumab (MED14736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. *J. Clin. Oncol.* 34 (26), 3119–3125. <https://doi.org/10.1200/JCO.2016.67.9761>.
- McCaffrey, J.A., Hilton, S., Mazumdar, M., Sadan, S., Kelly, W.K., Scher, H.I., et al., 1997. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. *J. Clin. Oncol.* 15 (5), 1853–1857. <https://doi.org/10.1200/JCO.1997.15.5.1853>.
- Milowsky, M.I., Rumble, R.B., Booth, C.M., Gilligan, T., Eapen, L.J., Hauke, R.J., et al., 2016. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology clinical practice guideline endorsement. *J. Clin. Oncol.* 34 (16), 1945–1952. <https://doi.org/10.1200/JCO.2015.65.9797>.
- National Cancer Institute. 2022 SEER Cancer Stat Facts: Bladder Cancer [<https://seer.cancer.gov/statfacts/html/urinb.html>].
- National Cancer Institute. 2022 Bladder Cancer Treatment (PDQ®) – Health Professional Version [Available from: (<https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq>)].
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Bladder Cancer, version 5.2021 - October 20, 2021. [Available from: (https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf)].
- NCT03898180 Cg. 2022 Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/LEAP-011) [Available from: (https://clinicaltrials.gov/ct2/history/NCT03898180?V_105=View#StudyPageTop)].
- Niegisch, G., Gerullis, H., Lin, S.W., Pavlova, J., Gondos, A., Rudolph, A., et al., 2018. A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. *J. Cancer* 9 (8), 1337–1348. <https://doi.org/10.7150/jca.23162>.
- O'Donnell, P.H., Balar, A.V., Vuky, J., Castellano, D., Bellmunt, J., Powles, T., et al., 2021. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. *J. Clin. Oncol.* 39 (Suppl 15) <https://doi.org/10.1200/JCO.2021.39.15.suppl.4508>.
- Patel, M.R., Ellerton, J., Infante, J.R., Agrawal, M., Gordon, M., Aljumaily, R., et al., 2018. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol.* 19 (1), 51–64. [https://doi.org/10.1016/S1470-2045\(17\)30900-2](https://doi.org/10.1016/S1470-2045(17)30900-2).
- Petrylak, D.P., de Wit, R., Chi, K.N., Drakaki, A., Sternberg, C.N., Nishiyama, H., et al., 2017. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. *Lancet* 390 (10109), 2266–2277. [https://doi.org/10.1016/S0140-6736\(17\)32365-6](https://doi.org/10.1016/S0140-6736(17)32365-6).
- Pfirsichke, C., Engblom, C., Rickelt, S., Cortez-Remamo, V., Garris, C., Pucci, F., et al., 2016. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. *Immunicity* 44 (2), 343–354. <https://doi.org/10.1016/j.immuni.2015.11.024>.
- Plimack, E.R., Bellmunt, J., Gupta, S., Berger, R., Chow, L.Q., Juco, J., et al., 2017. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. *Lancet Oncol.* 18 (2), 212–220. [https://doi.org/10.1016/S1470-2045\(17\)30007-4](https://doi.org/10.1016/S1470-2045(17)30007-4).
- Powles T. 2022, A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer [Available from: (<https://www.bartsccancer.london/centre-for-experimental-cancer-medicine/clinical-trial-portfolio/discus/>)].
- Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Lorig, Y., Cruz, C., et al., 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature* 515 (7528), 558–562. <https://doi.org/10.1038/nature13904>.
- Powles, T., Huddart, R.A., Elliott, T., Sarker, S.J., Ackerman, C., Jones, R., et al., 2017. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. *J Clin Oncol* 35 (1), 48–55. <https://doi.org/10.1200/JCO.2015.66.3468>.
- Powles, T., Durán, I., van der Heijden, M.S., Loriot, Y., Vogelzang, N.J., de Giorgi, U., et al., 2018. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 391 (10122), 748–757. [https://doi.org/10.1016/S0140-6736\(17\)33297-X](https://doi.org/10.1016/S0140-6736(17)33297-X).
- Powles, T., van der Heijden, M.S., Castellano, D., Galsky, M.D., Loriot, Y., Petrylak, D.P., et al., 2020. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol.* 21 (12), 1574–1588. [https://doi.org/10.1016/S1470-2045\(20\)30541-6](https://doi.org/10.1016/S1470-2045(20)30541-6).
- Powles, T., Park, S.H., Voog, E., Caserta, C., Valderrama, B.P., Gurney, H., et al., 2020. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *New Engl. J. Med.* 383 (13), 1218–1230. <https://doi.org/10.1056/NEJMoa2002788>.
- Powles, T., van der Heijden, M.S., Castellano, D., Loriot, Y., Galsky, M.D., Petrylak, D.P., et al., 2020. 6970 - A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). *Ann. Oncol.* 31 (Suppl 4), S550-S. <https://doi.org/10.1016/annonc/annonc274>.

- Powles, T., Kopytsov, E., Su, P., Parnis, F.X., Park, S.H., Yamamoto, Y., et al., 2020. 745P - Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC). *Ann. Oncol.* 31 (Suppl 4), S550-S. <https://doi.org/10.1016/annonc/annonc274>.
- Powles, T., Sridhar, S.S., Loriot, Y., Bellmunt, J., Mu, X.J., Ching, K.A., et al., 2021. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. *Nat. Med.* 27 (12), 2200–2211. <https://doi.org/10.1038/s41591-021-01579-0>.
- Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., et al., 2021. Bladder cancer: ESMO Clinical practice guideline for diagnosis, treatment and follow-up(†). *Ann. Oncol.* <https://doi.org/10.1016/j.annonc.2021.11.012>.
- Powles, T., Rosenberg, J.E., Sonpavde, G.P., Loriot, Y., Duran, I., Lee, J.L., et al., 2021. Enfortumab vedotin in previously treated advanced urothelial carcinoma. *New Engl. J. Med.* 384 (12), 1125–1135. <https://doi.org/10.1056/NEJMoa2035807>.
- Powles, T., Coszki, T., Ozguroglu, M., Matsubara, N., Geczi, L., Cheng, S.Y., et al., 2021. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 22 (7), 931–945. [https://doi.org/10.1016/S1470-2045\(21\)00152-2](https://doi.org/10.1016/S1470-2045(21)00152-2).
- Powles, T., Petrylak, D., Park, S.H., Sridhar, S.S., Caserta, C., Vuillemin, A.T., et al., 2021. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial. *J. Clin. Oncol.* 39 (15 Suppl) https://doi.org/10.1200/JCO.2021.39.15_suppl.4520.
- Powles, T., Carroll, D., Chowdhury, S., Gravis, G., Joly, F., Carles, J., et al., 2021. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. *Nat. Med.* 27 (5), 793–801. <https://doi.org/10.1038/s41591-021-01317-6>.
- Powles, T., Coszki, T., Ozguroglu, M., Matsubara, N., Geczi, L., Cheng, S.Y., et al., 2021. 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361. *J. Clin. Oncol.* 39 (6 Suppl) https://doi.org/10.1200/JCO.2021.39.6_suppl.450.
- Rodríguez-Vida, A., Saggese, M., Hughes, S., Rudman, S., Chowdhury, S., Smith, N.R., et al., 2015. Complexity of FGFR signalling in metastatic urothelial cancer. *J. Hematol. Oncol.* 8, 119. <https://doi.org/10.1186/s13045-015-0221-6>.
- Rose, T.L., Harrison, M.R., Deal, A.M., Ramalingam, S., Whang, Y.E., Brower, B., et al., 2021. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. *J. Clin. Oncol.* 39 (28), 3140–3148. <https://doi.org/10.1200/JCO.21.01003>.
- Rosenberg, J., Flaig, T.W., Friedlander, T.W., Milowsky, M.I., Srinivas, S., Petrylak, D.P., et al., 2020. Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. *J. Clin. Oncol.* 38 (6 Suppl) https://doi.org/10.1200/JCO.2020.38.6_suppl.441.
- Rosenberg, J., Sridhar, S.S., Zhang, J., Smith, D., Ruether, D., Flaig, T.W., et al., 2020. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. *J. Clin. Oncol.* 38 (10), 1041–1049. <https://doi.org/10.1200/JCO.19.02044>.
- Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al., 2016. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 387 (10031), 1909–1920. [https://doi.org/10.1016/S0140-6736\(16\)00561-4](https://doi.org/10.1016/S0140-6736(16)00561-4).
- Rosenberg, J.E., O'Donnell, P.H., Balar, A.V., McGregor, B.A., Heath, E.I., Yu, E.Y., et al., 2019. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. *J. Clin. Oncol.* 37 (29), 2592–2600. <https://doi.org/10.1200/JCO.19.01140>.
- Rosenberg, J.E., Galsky, M.D., Balar, A.V., Loriot, Y., Necchi, A., Hoffman-Censits, J., et al., 2021. 699P - Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II Imvigor210 study (cohort 1). *Ann. Oncol.* 32 (Suppl 5), S678–S724. <https://doi.org/10.1016/annonc/annonc675>.
- Rouanne, M., Bajorin, D.F., Hannan, R., Galsky, M.D., Williams, S.B., Necchi, A., et al., 2020. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. *Eur. Urol. Oncol.* 3 (6), 728–738. <https://doi.org/10.1016/j.euo.2020.06.009>.
- Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., Padala, S.A., Barsouk, A., 2020. Epidemiology of bladder cancer. *Med. Sci.* <https://doi.org/10.3390/medsci8010015>.
- de Santis, M., Bellmunt, J., Mead, G., Kerst, J.M., Leahy, M., Maroto, P., et al., 2009. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/ carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. *J. Clin. Oncol.* 27 (33), 5634–5639. <https://doi.org/10.1200/JCO.2008.21.4924>.
- de Santis, M., Bellmunt, J., Mead, G., Kerst, J.M., Leahy, M., Maroto, P., et al., 2012. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/ carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. *J. Clin. Oncol.* 30 (2), 191–199. <https://doi.org/10.1200/JCO.2011.37.3571>.
- Schreiber, R.D., Old, L.J., Smyth, M.J., 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* 331 (6024), 1565–1570. <https://doi.org/10.1126/science.1203486>.
- Sharma, P., Callahan, M.K., Bono, P., Kim, J., Spiropoulou, P., Calvo, E., et al., 2016. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. *Lancet Oncol.* 17 (11), 1590–1598. [https://doi.org/10.1016/S1470-2045\(16\)30496-X](https://doi.org/10.1016/S1470-2045(16)30496-X).
- Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., et al., 2017. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 18 (3), 312–322. [https://doi.org/10.1016/S1470-2045\(17\)30065-7](https://doi.org/10.1016/S1470-2045(17)30065-7).
- Simeone, J.C., Nordstrom, B.L., Patel, K., Mann, H., Klein, A.B., Horne, L., 2019. Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting. *Cancer Epidemiol.* 60, 121–127. <https://doi.org/10.1016/j.canep.2019.03.013>.
- Slater H. 2022. AstraZeneca withdraws durvalumab indication for previously treated locally advanced or metastatic bladder cancer [Available from: (<https://www.cancer-network.com/view/astrazeneca-withdraws-durvalumab-indication-for-previously-treated-locally-advanced-or-metastatic-bladder-cancer>)].
- Sonpavde, G., Pond, G.R., Choueiri, T.K., Mullane, S., Niegisch, G., Albers, P., et al., 2016. Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. *Eur. Urol.* 69 (4), 634–641. <https://doi.org/10.1016/j.eururo.2015.07.042>.
- Sridhar, S.S., Powles, T., Loriot, Y., Climent, M.A., Gupta, A., Tsuchiya, N., et al., 2021. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance. *J. Clin. Oncol.* 39 (Suppl 15) https://doi.org/10.1200/JCO.2021.39.15_suppl.4527.
- Stepan, L.P., Trueblood, E.S., Hale, K., Babcock, J., Borges, L., Sutherland, C.L., 2011. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. *J. Histochem. Cytochem.* 59 (7), 701–710. <https://doi.org/10.1369/0022155411410430>.
- Sternberg A. 2022. Atezolizumab indication in US withdrawn for previously treated metastatic urothelial cancer [Available from: (<https://www.cancer-network.com/view/atezolizumab-indication-in-us-withdrawn-for-previously-treated-metastatic-urothelial-cancer>)].
- Sternberg, C.N., de Mulder, P., Schornagel, J.H., Theodore, C., Fossa, S.D., van Oosterom, A.T., et al., 2006. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. *Eur. J. Cancer* 42 (1), 50–54. <https://doi.org/10.1016/j.ejca.2005.08.032>.
- Swami, U., Grivas, P., Pal, S.K., Agarwal, N., 2021. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. *Cancer Treat. Res. Commun.* 27, 100325 <https://doi.org/10.1016/j.ctarc.2021.100325>.
- Tomiyama, E., Fujita, K., Rodríguez Peña, M.D.C., Taheri, D., Banno, E., Kato, T., et al., 2020. Expression of nectin-4 and PD-L1 in upper tract urothelial carcinoma. *Int. J. Mol. Sci.* 21 (15) <https://doi.org/10.3390/ijms21155390>.
- Tonini, G., Imperatori, M., Vincenzi, B., Frezza, A.M., Santini, D., 2013. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. *J. Exp. Clin. Cancer Res.* 32, 92. <https://doi.org/10.1186/1756-9966-32-92>.
- Vaughn, D.J., Broome, C.M., Hussain, M., Gutheil, J.C., Markowitz, A.B., 2002. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. *J. Clin. Oncol.* 20 (4), 937–940. <https://doi.org/10.1200/JCO.2002.20.4.937>.
- Vukic, J., Balar, A.V., Castellano, D., O'Donnell, P.H., Grivas, P., Bellmunt, J., et al., 2020. Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. *J. Clin. Oncol.* 38 (23), 2658–2666. <https://doi.org/10.1200/JCO.19.01213>.
- Witjes, J.A., Bruins, H.M., Cathomas, R., Comperat, E.M., Cowan, N.C., Gakis, G., et al., 2021. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. *Eur. Urol.* 79 (1), 82–104. <https://doi.org/10.1016/j.eururo.2020.03.055>.
- World Health Organization. Bladder GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020. [Available from: (<https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf>)].
- Yu, E.Y., Petrylak, D.P., O'Donnell, P.H., Lee, J.L., van der Heijden, M.S., Loriot, Y., et al., 2021. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 22 (6), 872–882. [https://doi.org/10.1016/S1470-2045\(21\)00094-2](https://doi.org/10.1016/S1470-2045(21)00094-2).

Dr. Joaquim Bellmunt is presently Associate Professor at Harvard Medical School and Director of Bladder Cancer Program at Genitourinary Oncology Program of Beth Israel Deaconess Medical Center. He was the former Director of the Bladder Cancer Center at Dana-Farber Cancer Institute. Clinical expertise focuses on urological diseases, particularly prostate, bladder and kidney cancer. Extensive experience treating prostate and bladder cancer patients and he has been a key investigator in several trials conducted in this patient population. He has been involved in the development of immunotherapy in bladder cancer since its inception. He participated on the two phase I trials with atezolizumab (Nature, 2014) and with pembrolizumab (The Lancet Oncol. 2017) and the phase II atezolizumab (The Lancet 2016) that lead to the FDA approval and that I also co-authored. Along the same line, he has contributed to the development of these agents in unfit bladder cancer patients (The Lancet. 2017). One of his most important contributions in bladder cancer has been to be the Chair and lead investigator of the phase III randomized study of immunotherapy (pembrolizumab) versus chemotherapy. This is a landmark trial showing survival superiority for immunotherapy versus chemotherapy. The results were published in the New England Journal of Medicine (Bellmunt J, New Engl J Med 2017). He is also the principal investigator of the study Imvigor 010 (adjuvant atezolizumab in bladder cancer). He is a member of the American Society of Clinical Oncology (ASCO), the European

Society of Medical Oncology (ESMO), the Spanish Society of Medical Oncology (SEOM) and the Spanish Oncology Genitourinary Group (SOGUG).

Dr. Begoña P. Valderrama was graduated in Medicine and Surgery at the University of Cantabria (Spain) in 2001 and obtained his specialty in Medical Oncology at Virgen del Rocío University Hospital in 2006. She is currently working at Virgen del Rocío University Hospital where she is Senior Staff Physician. Her main research activities are in Genitourinary cancers. She is a member of the Spanish Oncology Genitourinary Group (SOGUG), and she is part of the Board of Directors. She is member of the Spanish Immuno-biological Cancer Therapies Group (GETICA), the Spanish Society of Medical Oncology (SEOM), the Andalusian Society of Medical Oncology (SAOM), and the European Society for Medical Oncology (ESMO).

Dr. Javier Puente was born in Madrid (Spain) in 1977. He received his medical degree in 2001 at the Complutense University of Madrid (Spain) followed by his fellowship in 2002. Dr. Puente earns his Doctorate in Medicine (Ph.D.) with a mention of "Cum Laude" in 2007. Dr. Puente served as resident in the Medical Oncology Department at San Carlos Clinic Hospital from 2002 to 2006 at which point he became one of the clinical lead and researcher in the Genitourinary Cancer Unit. Today, he is the Director of the Institute of Oncology at that hospital and his activities are focused on the management and treatment of patients with all GU tumors. In addition to the Spanish Society of Medical Oncology (SEOM) and the Spanish National Cancer Research Center (CNIO), Dr. Puente is also a member of the Spanish Oncology Genitourinary Group (SOGUG), the American Society of Medical Oncology (ASCO) and the European Society of Clinical Oncology (ESMO).

Dr. Enrique Grande graduated in Medicine and Surgery at the Autónoma University of Madrid (Spain) in 1999 and obtained his specialty in Medical Oncology at San Carlos Clinic Hospital of Madrid in 2005. He is currently working at MD Anderson Cancer Center Madrid where he is the Head of the Medical Oncology Department. His main research activities are in Genitourinary cancers and Endocrine tumors. He obtained his Ph.D. in Medicine in a work of Interactions on the route of drug metabolism of anti-cancer targets, as a strategy to reduce the dose and total cost: sunitinib and ketoconazole. He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Clinical Oncology (ESMO), the European Neuroendocrine Tumor Society (ENETS), the American Association of Cancer Research (AACR), the Spanish Neuroendocrine and Endocrine Tumors Group (GETNE), the Spanish Oncology Genitourinary Group (SOGUG), the Spanish Group of Infrequent Orphan Tumors (GETHI) and the Spanish Society of Medical Oncology (SEOM).

Dr. M. Victoria Bolós graduated in Biochemistry at the Autónoma University of Madrid (Spain) in 2001 and in Molecular Biology in 2003. She has a strong background as a researcher in translational oncology. She obtained her Ph.D. in biochemistry in 2006 at the Autónoma University of Madrid (Spain) with the highest commendation after a 5-year pre-doctoral position at the Spanish National Research Council (CSIC) and then she spent more than 2 years as a post-doctoral researcher at the Spanish National Centre of Biotechnology. She has more than 12-year industry experience in the oncology field. She is currently working as a Senior Medical Advisor in charge of Genitourinary and Gastrointestinal tumors as well as Early Drugs at Pfizer Oncology, Madrid (Spain).

Dr. Nuria Lainez graduated in Medicine and Surgery at the University of Zaragoza (Spain) in 1992 and obtained his specialty in Medical Oncology at Sant Joan de Reus Hospital in 1998. She is currently working at Navarra University Hospital where she is Clinical chief. Her main research activities are in Genitourinary cancers and Gynecological cancer. She is a member of the Spanish Society of Medical Oncology (SEOM), the Spanish Oncology Genitourinary Group (SOGUG), the Spanish Research Group on Ovarian Cancer (GEICO), the European Organization for Research and Treatment of Cancer Genitourinary Cancer Groups (EORTC GUCC) and member of GO Norte.

Dr. Sergio Vázquez graduated in Medicine and Surgery at the University of Santiago de Compostela (Spain) in 1987 and obtained his specialty in Medical Oncology at Gipuzkoa

Oncology Institute Hospital in 1990. He is currently working at Lucus Augusti University Hospital where he is Head of Medical Oncology Service and Radiation Oncology Service Coordinator. His main research activities are in Genitourinary cancers and Lung cancers. He is a member of the Spanish Oncology Genitourinary Group (SOGUG), the Spanish Society of Medical Oncology (SEOM) and Oncology Society of Galicia (SOG).

Dr. Pablo Maroto graduated in Medicine and Surgery at the University of Santiago de Compostela (Spain) in 1990 and obtained his specialty in Medical Oncology at Sant Pau Hospital in 1996. He is currently working at Sant Pau Hospital (Barcelona) where he is in charge of the area of Uro-Oncology. His main research activities are in Genitourinary cancers. He obtained his Ph.D. in 1999. He is a presently the Chair of the European Organization for Research and Treatment of Cancer Genito Urinary Cancer Groups (EORTC GUCC), and member of the Spanish Society of Medical Oncology (SEOM), the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). Dr. Maroto is also Associate Professor of medicine at the Autònoma University of Barcelona.

Dr. Miguel Ángel Climent, graduated in Medicine and Surgery at the University of Valencia (Spain) in 1987 and obtained his specialty in Medical Oncology at Santa Creu and Sant Pau Hospital in 1992. He is currently working at the Valencian Oncology Institute where he is Medical Oncologist Chief in Genitourinary tumors. His main research activities are in Genitourinary cancers. He obtained his Ph.D. in Medicine. He is a member of the Spanish Society of Medical Oncology (SEOM), the Spanish Oncology Genitourinary Group (SOGUG) and the Spanish Germinal Cancers Group.

Dr. Xavier García del Muro graduated in Medicine and Surgery at the University of Barcelona (Spain) in 1982 and obtained his specialty in Medical Oncology at San Carlos University Hospital in Madrid in 1988. He is currently working at the Catalan Institute of Oncology in Barcelona where he is Head of the Genitourinary Cancer Unit and Professor of the University of Barcelona. His main research activities are in Genitourinary cancer and Sarcoma. He obtained his Ph.D. in Medicine in 2004. He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the European Organisation for Research and Treatment of Cancer (EORTC).

Dr. José Ángel Arranz graduated in Medicine and Surgery at the University of Valladolid (Spain) in 1985 and obtained his specialty in Medical Oncology at Gregorio Marañón University Hospital in 1991 in Madrid, Spain. He is currently working at Gregorio Marañón University Hospital where he is Head of the Genitourinary Tumors Section. His main research activities are in Genitourinary and Gynecologic cancers. He obtained his Ph. D. in Medicine (Complutense University of Madrid, Spain). He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the Spanish Society of Medical Oncology (SEOM) and the Spanish Oncology Genitourinary Group (SOGUG).

Dr. Ignacio Durán graduated in Medicine and Surgery at the University of Salamanca (Spain) in 1997 and obtained his specialty in Medical Oncology at Son Dureta University Hospital in 2002. He is currently working at Marqués de Valdecilla University Hospital in Santander (Spain) where he is the GU Oncology Group Head in the Medical Oncology Department. His main research activities are in Genitourinary cancers and in clinical and translational research. He obtained his Ph.D. in Medicine in 2005 at the Complutense University of Madrid (Spain) with highest commendation. He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the European Association of Urology (EAU), the European Association of Cancer Research (EACR) and the Spanish Society of Medical Oncology (SEOM). He serves in the board of directors of the Spanish Society of Research in Cancer (ASEICA) and of the Spanish Germ Cell Cancer Group (GG). He is the president and co-founder of GO Norte oncology cooperative group since January 2020.